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Zusammenfassung 
 
Die Entwicklung von Krebs erfolgt schrittweise und beinhaltet das Zusammenspiel von ver-
schiedenen Mutationen, die der Zelle erlauben Fähigkeiten zu erwerben, die man als Marken-
zeichen von Krebs bezeichnet: sie produziert ihre eigenen Wachstumsfaktoren, wird unemp-
findlich gegenüber wachstumshemmenden Signalen, kann dem Zelltod entkommen oder aus 
ihrem Ursprungsgewebe auswandern. Um herauszufinden, wie Zellen diese Markenzeichen 
erwerben, müssen in vivo Modelle entwickelt werden, welche die Krebsentwicklung wider-
spiegeln. Die Maus ist unumstritten das beste Modell um diese Frage zu untersuchen, jedoch 
ist es schwierig und sehr zeit- und arbeitsaufwendig krebsverursachende Gene zu erforschen. 
Einfachere Tiermodelle, wie Drosophila, können hier weiterhelfen und die Entdeckung von 
neuen, krebs-relevanten Genen beschleunigen. 
 
Wird eine konstant aktive Form des Onkoproteins Ras (RasV12) im Epithelgewebe von Dro-
sophila exprimiert und mit Mutationen im Tumorsuppressorgen scribbled (scrib) kombiniert, 
entstehen grosse, metastasierende Tumore, die gewisse Ähnlichkeiten mit menschlichen 
Krebsformen aufweisen. Vor kurzem wurde herausgefunden, dass diese Tumore von der Ak-
tivität des c-Jun N-terminale Kinase (JNK) Signalwegs abhängen. Dieser aktiviert Matrixme-
talloproteinasen (Mmp1) und Zytokine, welche das Krebswachstum begünstigen. 
 
In unserem Labor ist eine veränderte Version dieses RasV12 scrib-/- Modells entwickelt wor-
den, die anstelle von Mutationen eine RNAi gegen disc-large (dlg) benützt. Mit diesem Mo-
dell haben wir 100 Gene mit RNAi getestet und zehn Gene identifiziert, die das Tumorwachs-
tum hemmen, wenn man ihr Genprodukt erschöpft. In der vorliegenden Arbeit haben wir ei-
nes dieser Gene funktionell charakterisiert und angefangen ein zweites Kandidatengen zu 
analysieren. Zusätzlich haben wir getestet, ob der Tumor Nekrosis Faktor (TNF) Rezeptor 
Wengen (Wgn) das Wachstum von RasV12 dlgRNAi Tumoren beinflusst. 
 
Der Hauptteil dieses Projektes befasst sich mit der Rolle des Transkriptionsfaktors Ets21C im 
Tumorwachstum. ETS Proteine sind eine grosse Familie von Transkriptionsfaktoren, die auch 
für gewisse menschliche Krebsformen wichtig sind. Wir zeigen, dass Ets21C sowohl für das 
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Krebswachstum benötigt wird, als auch ausreicht, um das Wachstum zu verstärken. Die Ex-
pression von Ets21C ist in neoplastischen Tumoren erhöht, was auf die Aktivität des JNK 
Signalwegs zurückzuführen ist. Ausserdem haben wir herausgefunden, dass Zielgene des JNK 
Signalwegs wie Mmp1, Pvf1 oder upd1 durch Ets21C induziert werden, möglicherweise 
durch Kooperation mit dem JNK Transkriptionsfaktor AP-1. Besonders hervorzuheben ist 
hier, dass die Aktivierung der Zielgene von der PNT und ETS Domaine von Ets21C abhängt. 
Vorläufige Daten deuten auch darauf hin, dass Ets21C in der regulatorischen Region von 
Mmp1 bindet, was eine Rolle von Ets21C als nukleärer Effektor des JNK Signalwegs bestäti-
gen würde.  
 
Astrocytic leucin-rich repeat module (alrm) ist das zweite Kandidatengen, das wir angefangen 
haben zu charakterisieren. RNAi gegen alrm reduziert das Krebswachstum, beeinträchtigt 
jedoch normales Gewebe nicht. Um diese Erkenntnis zu bestätigen, haben wir ein mutantes 
Allel und unabhängige RNAi Linien von alrm hergestellt. Zusätzlich, haben wir einen Zu-
sammenhang zwischen Alrm und der Aktivität des JNK Signalwegs gefunden.  
 
Der letzte Teil dieser Arbeit beschreibt die Identifizierung von Grindelwald (Grnd), einem 
neuen Drosophila Tumor Nekrosis Faktor (TNF) Rezeptor. Wir haben zu dieser Studie einige 
Experimente beigesteuert und zeigen, dass die Aktivierung des JNK Signalwegs in neoplasti-
schen RasV12 dlgRNAi Tumoren ausschliesslich von Grnd und nicht von Wengen (Wgn) ab-
hängt. Wgn wurde ursprünglich als Drosophila TNF Rezeptor beschrieben, diese Daten konn-
ten jedoch nie bestätigt werden. 
 
Unsere Resultate haben neue Komponenten identifiziert, die wichtig für das Wachstum von 
neoplastischen Tumoren sind und tragen mechanistische Erkenntnisse zur Funktion des JNK 
Signalwegs bei.  
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Summary 
 
The development of cancer is a multistep process, involving the cooperation of mutations that 
allow cells to acquire capabilities that are considered hallmarks of cancer, such as self-
sufficiency in growth signals, insensitivity to anti-growth signals, evasion of apoptosis, limit-
less replicative potential, sustained angiogenesis, and tissue invasion and metastasis (Hanahan 
& Weinberg, 2000, 2011). To elucidate the steps involved in acquiring these hallmarks, in 
vivo models need to be developed that recapitulate tumorigenesis. Although the optimal mod-
el system is currently the mouse, simpler animal model systems, such as Drosophila, that 
mimic some of the characteristics of mammalian tumorigenesis provide a means to more rap-
idly uncover novel cancer-relevant genes in an in vivo setting (Brumby & Richardson, 2005).  
In epithelial tissues in Drosophila, cooperation between the oncogenic protein RasV12 and 
loss-of-function mutations in the conserved tumor suppressor gene scribbled (scrib) gives rise 
to metastatic tumors that display many of the characteristics observed in human cancers 
(Pagliarini, 2003; Brumby & Richardson, 2003). More recently it was found that the interac-
tion between RasV12 scrib-/- clones involves JNK signaling propagation and upregulation of 
Mmp1 and JAK/STAT-activating cytokines (Igaki et al, 2006; Wu et al, 2010).  
 
Our laboratory has established a modified version of the RasV12 scrib-/- model that used an 
RNAi that targets dlg (Willecke et al, 2011). Using this model we have screened 100 genes 
with RNAi and identified ten genes that suppressed tumor growth upon depletion of the gene 
product (Master Thesis J. Toggweiler). In the study presented here, we have functionally 
characterized one of these candidates and started to evaluate a second suppressor. In addition, 
we tested a role of the tumor necrosis factor (TNF) receptor Wengen (Wgn) in RasV12 dlgRNAi 
tumors. 
 
The major part of this thesis describes the role of the transcription factor Ets21C in neoplastic 
growth. ETS proteins are a large family of transcription factors that are relevant for certain 
types of human cancers (Kar & Gutierrez-Hartmann, 2013). We show that Ets21C is neces-
sary for neoplastic growth and sufficient to enhance tumor growth. Ets21C is upregulated in 
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neoplastic tumors as a consequence of JNK signaling activity. Furthermore, we find that 
downstream targets of the JNK pathway such as Mmp1, Pvf1 or upd1 are induced by Ets21C 
possibly via cooperation with the JNK transcription factor AP-1. Importantly, target gene in-
duction depends on the PNT and ETS domain of Ets21C. Preliminary data also suggest bind-
ing of Ets21C in the Mmp1 regulatory region, which would further support a function for 
Ets21C as nuclear effector of the JNK pathway.  
 
The second candidate that we started to evaluate is Astrocytic leucin-rich repeat module 
(Alrm). An RNAi targeting alrm reduced growth of RasV12 dlgRNAi tumors, but did not affect 
wild-type tissue. To confirm this finding, we have generated a mutant allele and independent 
RNAi lines of alrm. In addition, we assessed a role for Alrm in regulating the activity of the 
JNK pathway by monitoring Mmp1 and Ets21C expression.  
 
The third part of this thesis is a manuscript that has identified Grindelwald (Grnd), a new 
Drosophila tumor necrosis factor (TNF) receptor. We have contributed experiments to this 
study showing that neoplastic RasV12 dlgRNAi tumors depend on Grnd to activate the JNK 
pathway, but not on Wgn. Wgn was  initially reported to be the Drosophila TNF receptor.  
 
Our results uncovered novel players in regulating neoplastic tumor growth and added im-
portant mechanistic insights how JNK signaling is transduced and leads to the activation of 
distinct sets of target genes. 
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1 Introduction 
 
1.1 Studying tumor growth in Drosophila 
 
Tumor progression is a multistep process, which is caused by the accumulation of genetic 
alterations over time. Such mutations commonly perturb the signaling pathways that are re-
sponsible for the regulation of proliferation, cell death or tissue homeostasis. Based on this, 
six hallmarks have been proposed that are associated with malignant transformation: Self-
sufficiency in growth, insensitivity to anti-growth signals, evasion of apoptosis, metastasis 
and invasion, sustained angiogenesis and limitless replicative potential (Hanahan & 
Weinberg, 2000). Drosophila has made seminal contributions to the understanding of certain 
aspects of tumorigenesis by helping reveal the function of oncogenes and tumor suppressor 
genes during normal development. For example, many components of the recently identified 
Salvador/Warts/Hippo (SWH) pathway have initially been found through genetic screens in 
flies. Inactivation of warts (wts) or hippo (hpo) causes hyperplastic growth of imaginal discs 
and adult organs, highlighting an crucial tumor suppressive role of this pathway (Udan et al, 
2003; Justice et al, 1995). Orthologs of many other components have later also been identified 
in mammals and investigations in cell lines or mouse models point towards a similar role of 
the analogous human pathway in tumorigenesis (Harvey et al, 2013). 
 
Cancer is an age-dependent disease and multiple hits are necessary to transform a healthy cell 
into a malignant derivative. Due its short lifespan Drosophila only rarely develops natural 
tumors and is not useful to study de novo tumorigenesis (Salomon & Jackson, 2008). Howev-
er, the large collection of available genetic tools in flies provides an excellent resource to gen-
erate and investigate neoplastic tumors via defined genetic mutations. Binary expression sys-
tems such as the Gal4/UAS or LexA/LexO allow spatial and temporal control of gene expres-
sion; mitotic recombination enables the generation of genetic mosaics consisting of wild-type 
and mutant cell populations next to each other (Lee & Luo, 1999; Lai & Lee, 2006; Brand & 
Perrimon, 1993). Such a situation is reminiscent of the early development of tumors where a 
single cell acquires a mutation and has to survive within the remaining wild-type cells. A 
number of tumor models have therefore been established – in larval stages as well as in adult 
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organs – that rely on defined genetic modifications, which activate or shut-down specific sig-
naling pathways that have been associated with cancer. These models have been used to either 
screen for new pathway components involved in tumor formation or for new chemical inhibi-
tors that can block a specific form of tumors. Recently, Drosophila has also been utilized in 
whole animal screens to test small molecule inhibitors for efficacy and toxicity (Gladstone et 
al, 2012; Willoughby et al, 2012). Although the mouse is undeniably the optimal model for 
studying tumorigenesis, Drosophila provides a more rapid means for identifying in vivo rele-
vant pathway components and pre-screening of drugs to sort out toxic compounds could help 
close the gap between cell culture and mouse models.  
The following sections describe current Drosophila tumor models with a focus on imaginal 
disc based models, as those are most relevant for this thesis. 
 
1.1.1 Imaginal disc based models  
 
Imaginal discs are the primordia for the adult organs such as the wing, eye or leg and consist 
of epithelial cells arranged in a 2D sheet-like structure. Tumorous growth of imaginal discs 
can be classified into hyperplastic or neoplastic (Gateff, 1994). Hyperplastic growth occurs if 
epithelial cells expand beyond their normal limitations, but still retain apical-basal organiza-
tion and the ability to differentiate. Overexpression of oncogenic RasV12 or loss of wts or 
phosphatase and tensine homolog (Pten) produces a hyperplastic epithelium (Pagliarini, 
2003; Justice et al, 1995; Goberdhan et al, 1999). Neoplastic growth denotes excessive prolif-
eration of epithelial cells that have lost polarity and breach basement membranes. These cells 
grow into multi-layered tumors and are not able to differentiate. Neoplastic growth is 
achieved by a loss of a so called neoplastic tumor suppressor genes. The earliest tumor sup-
pressor gene identified in flies was lethal giant larvae (lgl). Later it was found to regulate 
apico-basal polarity together with scribbled (scrib) and discs-large (dlg) (Gateff, 1978; 
Bilder, 2000). Homozygous mutant lgl larvae display overgrown imaginal discs and do not 
enter metamorphosis, but instead grow into giant larvae (Gateff, 1978). Other neoplastic tu-
mor suppressor genes besides the polarity genes scrib, dlg or lgl, are required for endocytosis 
like avalanche (avl), Rab5 or Vacuolar protein sorting 25 (Vps25) (Woods & Bryant, 1991; 
Bilder & Perrimon, 2000; Thompson et al, 2005; Gateff, 1978; Lu & Bilder, 2005).  
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1.1.1.1 Eye discs – cooperation of RasV12 and scrib-/- 
 
The Drosophila eye imaginal disc and adult eye are an excellent tissue to carry out genetic 
screens aiming at investigating gene function. They have also been used to study tumor 
growth. Work of two groups has been seminal in this regard. Both describe the generation of 
tumor cells in otherwise wild-type tissue to study the cooperation between oncogenes and 
tumor suppressor genes and to identify additional components that modify tumor develop-
ment (Brumby and Richardson, 2003; Pagliarini and Xu, 2003).  
Pagliarini and Xu generated non-invasive tumors by inducing clones of cells that express an 
active form of the Drosophila Ras homolog (Ras85DG12V), further referred to as RasV12. This 
leads to constitutive active Ras signaling, which results in overgrowth and benign tumors. As 
a next step they were interested whether additional genetic alterations were able to transform 
the non-invasive tumor cells into metastatic derivatives. Mutations in the neoplastic tumor 
suppressor gene scrib and concomitant activation of RasV12 resulted in large primary tumors 
and groups of cells located at distant sites, mainly in the ventral nerve cord (VNC) and in the 
brain lobes, which suggested that the tumor cells had acquired the ability to metastasize. Fur-
thermore, RasV12 scrib-/- tumors displayed lower expression levels of E-cadherin (E-cad) and 
showed a degradation of the basement membrane. Both are characteristics of metastatic 
mammalian tumors (Egeblad and Werb, 2002; Perl et al., 1998). Combining scrib mutant 
cells with other growth-promoting genes, such as dMyc or dAkt, lead to overgrowth, but no 
invasive capabilities. Thus, the metastasis-promoting effect of mutant scrib seems to specifi-
cally depend on its cooperation with RasV12. 
Brumby and Richardson obtained similar results by generating scrib-/- clones in eye imaginal 
discs and testing if secondary oncogenic mutations could rescue scrib-/- cells from apoptosis 
by ectopically activating the major growth and pattering pathways, such as Wingless (Wg), 
epidermal growth factor receptor (EGFR) or Decapentaplegic (Dpp). Scrib-/- cells are usually 
not tolerated by the neighbouring wild-type cells and eliminated by c-Jun N-terminal kinase 
(JNK) mediated cell death, ensuring tissue integrity and preventing uncontrolled growth. The 
strongest cooperation with scrib-/- was seen with constitutive active forms of Ras or Notch:  
RasV12 scrib-/- or NotchACT scrib-/- cells hyperproliferated, failed to differentiate, grew in three 
dimensions and fused with adjacent tissue (Brumby & Richardson, 2003) 
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The cooperative nature of RasV12 and scrib mutations has subsequently been studied by many 
groups and produced valuable insights into the complex interplay of the two signaling path-
ways. RasV12 scrib-/- tumors express matrix metalloproteinase 1 (Mmp1) required for degrad-
ing extracellular matrix proteins, thus endowing tumor cells with invasive capabilities 
(Uhlirova & Bohmann, 2006). Mmp1 expression is regulated by the JNK pathway, the latter 
is activated as a consequence of loss of polarity (Uhlirova & Bohmann, 2006; Igaki et al, 
2006) (Fig.1). Furthermore, JNK activity is responsible for the cell autonomous induction of 
Unpaired (Upd) cytokines, Upd1, Upd2 and Upd3, that substantially contribute to tumor 
growth by activating the JAK/STAT pathway (Wu et al, 2010). More recently, JNK signaling 
has also been proposed to regulate Pvf1 expression, thereby regulating the proliferation of 
hemocytes, the immune cells of Drosophila that are recruited to tumors (Parisi et al, 2014; 
Pastor-Pareja et al, 2008; Cordero et al, 2010). The flies innate immune system is thought to 
act as crucial anti-tumor defense; increased numbers of hemocytes restrict growth of scrib-/- or 
dlg-/- tumors by producing the Toll ligand Spätzle (Spz) and Eiger (Egr) proteins that induce 
an innate immune response in the larval fat body or cause cell death of tumor cell, respective-
ly (Parisi et al, 2014) (Fig. 1, A). This shows important parallels to the human innate and 
adaptive immune responses that act as a first-line defense against emerging tumor cells 
(Swann & Smyth, 2007).  
 
Recent efforts in our laboaratory have led to the establishment of a tumor model that is based 
on RasV12 and an RNAi targeting dlg. This model gives rise to similar phenotypes as the 
RasV12 scrib-/- model, but facilitated screening of additional RNAi or overexpression lines in 
only one generation. Utilizing this system, we have uncovered that tumor cells are sensitive to 
reductions in PI3K pathway activity while normal cells are not (Willecke et al, 2011). The 
same model also led to the identification of the transcription factor Ets21C as a critical regula-
tor of tumor growth, possibly by cooperating with the AP-1 transcription factor (this thesis, 
Toggweiler et al., in prep.) (Fig. 1, A). Ets21C has also been proposed to mediate oncogenic 
growth and invasion by Kühlshammer et al. along with the nuclear receptor Ftz transcription 
factor 1 (Ftz-F1) that could mediate Hippo signaling (Kulshammer et al, 2015). The involve-
ment of the Hippo pathway in regulating scrib-/- and RasV12 scrib-/- tumor growth has been 
demonstrated by several groups, but the how has been under debate. Sun and Irvine proposed 
that JNK signaling inhibits wts, leading to enhanced growth by elevating Yki activity whereas 
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Doggett et al. propose that loss of polarity impairs Hippo signaling via JNK independent 
mechanisms (Sun & Irvine, 2011; Doggett et al, 2011). Yet another publication reported that 
in scrib-/- cells wts is activated by JNK signaling and restricts tumor growth while in the pres-
ence of RasV12, JNK signaling enhances the activity of the Hippo effector Yorkie (Yki) by 
promoting the accumulation of filamentous actin (F-actin) (Enomoto et al, 2015). Clearly, 
changes in actin cytoskeletal dynamics regulate normal organ growth and tumor growth: En-
hanced F-actin affects organ growth by upregulating Yki activity and loss of the actin cross-
linker Cheerio (Cher) interferes with RasV12 scrib-/- tumor growth (Fernández et al, 2011; 
Kulshammer & Uhlirova, 2013; Sansores-Garcia et al, 2011). Similar results have been sub-
sequently obtained in mammalian cells, highlighting the power of Drosophila models to un-
cover mechanisms relevant to human tumors (Wada et al, 2011). Panel A in Figure 1 provides 
a simplified overview of the pathways and components that are active in RasV12 scrib-/- cells. 
 
Although used extensively for genetic screens, RasV12 scrib-/- tumor models have only rarely 
been used for screening therapeutic compounds. In a pilot screen of 2000 compounds 
Willoughby et al. have identified the glutamine analogue acivicin as a potent inhibitor of tu-
mor growth in Drosophila (Willoughby et al, 2012). Chemical screens have also provided 
valuable results in a Drosophila model of multiple endocrine neoplasia type 2 (MEN2), which 
is a hereditary form of thyroid cancer. Ret, the underlying tyrosine kinase that is active in 
MEN2 was targeted to the Drosophila eye, resulting in a “rough eye” phenotype due to en-
hanced proliferation and defects in differentiation. Signaling through the Ret kinase activates 
a broad spectra of pathways including Ras, Src, JNK and Hedgehog (Read et al., 2005) (Fig. 
1, B). To test its usefulness for screening compound libraries, a small set of known therapeu-
tics has been tested. Vandetanib (ZD6474) was validated as being efficient in blocking Ret 
dependent tumorigenesis (Vidal, 2005). Based on these results, the MEN2 model has been 
improved for drug screening and a whole library of polypharmacological compounds has been 
tested for efficacy and toxicity. AD57, one of the most promising candidates, has further been 
characterized and based on these results analogs have been developed that only block the ki-
nases relevant for the MEN2 phenotype but spared mTor whose inhibition was associated 
with severe toxicity (Dar et al, 2012). Panel B of Figure 1 summarizes the pathways that are 
activated upon RetMEN2 expression.  
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Figure 1: Schematic depiction of Drosophila eye disc based tumor models. (A) RasV12 scrib-/- model: loss of 
scrib causes loss of polarity and activates the JNK pathway via the TNF receptor Grnd. JNK activity leads to 
the induction of downstream effectors such as Mmp1, Ets21C, Upd1 and Pvf1 that collectively contribute to 
tumorigenesis and invasion. (B) RetMEN2 model: targeted expression of Ret in the GMR domain of eye imag-
inal disc activates several downstream signaling modules such as Ras, PI3K and Src that stimulate prolifera-
tion and invasive behavior. 
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1.1.1.2 Wing discs  
 
Not only the Drosophila eye, but also the wing has been studied in great detail and yielded 
many pivotal findings on organ growth and patterning during development (Neto-Silva et al, 
2009). It is therefore not surprising that the wing disc has been exploited to analyze tumor 
growth. The syntaxin Avalanche (Avl) functions in the early endocytic machinery and a loss 
of avl gives rise to neoplastic tumors due to an expansion of the apical domain, which leads to 
a disorganization of cell polarity (Lu & Bilder, 2005) (Fig. 2). This phenotype has been uti-
lized by the Léopold group for a genome-wide RNAi screen for modifiers of neoplastic 
growth. Targeting an avlRNAi to the developing wing induces a developmental delay of 2-3 
days as a consequence of neoplastic tumor formation. An RNAi targeting the Dilp8 gene, 
which encodes an insulin-like peptide, rescued the developmental delay, but not neoplastic 
growth. Further investigations revealed a key function for Dilp8 in coordinating growth with 
developmental timing, demonstrating that Drosophila tumor models are not only useful in 
deciphering mechanisms of tumor growth, but also yield other unexpected findings about 
fundamental biological processes (Colombani et al, 2012) (Fig. 2). Dilp8 was identified inde-
pendently in yet another Drosophila tumor model. Concomitant activation of the Notch ligand 
Delta together with two neighboring epigenetic repressors pipsqueak (psq) and longitudinals 
lacking (lola) in eye discs leads to massive overgrowth and metastasis (Ferres-Marco et al, 
2006). Microarrays revealed a strong enrichment of Dilp8 in tumors and subsequent analyses 
reached similar conclusions as the Léopold group (Garelli et al, 2012).  
The genome-wide screen of the Léopold laboratory has revealed an additional interesting 
candidate gene, grindelwald (grnd) (Fig. 2). Loss of function of grnd rescued both, the devel-
opmental delay as well as neoplastic growth of avlRNAi tumors. Grnd is a transmembrane pro-
tein, harboring a cysteine-rich domain (CRD) that is homologous to the vertebrate TNFRs. 
Grnd was therefore suspected to mediate TNF signaling in Drosophila. Indeed, grndRNAi sup-
pressed the small eye phenotype caused by targeted expression of the Drosophila TNF alpha 
homolog Egr to the Drosophila eye and was found to associate with TRAF2, the most up-
stream component of the JNK pathway. Furthermore, RasV12 scrib-/- tumors were found to 
critically depend on Grnd function. In this context, Grnd seems to be activated independently 
of Egr, but through interaction with an apical polarity complex consisting of Crumbs (Crb), 
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Stardust (Std) and Patj, providing for the first time a link between defects in polarity and the 
activation of the JNK pathway (Andersen et al, 2015) (Fig. 2).  
 
 
  
 
 
Figure 2: Schematic depiction of a Drosophila wing disc based model: Depletion of the syntaxin Avl in the 
rotund (rn) expression domain results in an expansion of the apical domain most likely due to defective 
endosomal degradation of apical determinants such as Crumbs (Crb). As a consequence, Wingless (Wg) and 
JNK signaling are activated and lead to overgrowth and invasion through degradation of the basement 
membrane. The activation of the JNK pathway also provokes a developmental delay by inducing the ex-
pression of the insulin-like peptide Dilp8. EE: early endosome, LE: late endosome, Lys: lysosome. 
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1.1.2 Details of our tumor model 
 
Pagliarini and Xu, and Brumby and Richardson used the MARCM system to generate RasV12 
scrib-/- tumors (Lee and Luo, 1999). To analyse the effect of additional genes on growth of 
RasV12 scrib-/- tumors with this system, two generations of fly crosses are necessary, which is 
not well suited for a large screen. As mentioned above, our laboratory has modified the genet-
ic setup so that all the components needed to generate a neoplastic phenotype are present in 
one fly strain (Willecke et al, 2011). Additional transgenes such as RNAi lines or cDNA`s 
can easily be crossed to this tester stock and be analysed in one generation. The tester stock 
overexpressed RasV12 and a dsRNA construct targeting dlg. To specifically create tumors in 
the eye discs, we expressed a Flp recombinase driven by the eyeless (ey) promoter, which 
flipped out a stop cassette between two FRT sites. This led to the expression of Gal4 driven 
by the actin5c (act) promoter. Gal4 drives UAS-RasV12, UAS-dlgRNAi and UAS-GFP which 
was used to visualize the tumor tissue (Fig. 3, A). We used UAS-dlgRNAi because there was no 
suitable RNAi line available for scrib. As reported for the original tumor models, the tumor-
carrying larvae showed a developmental delay and were often not able to pupariate, but con-
tinued to grow for up to 10 days after egg laying (AEL) and died as giant larva (Brumby and 
Richardson, 2003; Pagliarini and Xu, 2003). Animals that managed to pupariate died as pupae 
and never reached adulthood. In order to maintain the tester stock, Gal4 had to be prevented 
from activating RasV12 and dlgRNAi. The stock therefore has been balanced with a chromosome 
that carries Gal80, the transcriptional repressor of Gal4, under the control of the tubulin (tub) 
promoter. 
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1.2 The ETS family of transcription factors 
 
The main part of this thesis describes the characterization of the Drosophila ETS protein, 
Ets21C. The following sections will therefore provide a general overview on the ETS tran-
scription factor family, describe the family members in Drosophila and discuss what was 
known about their relevance in cancer. 
 
1.2.1 Structure and function of human ETS proteins  
 
The ETS family is a family of transcription factors unique to Metazoans. ETS stands for “E-
twenty-six”, since the founding member of the family, Ets-1, was identified as an oncogene 
(v-Ets) transduced by the avian eurythroblastosis virus E26 (Leprince et al, 1983; Nunn et al, 
1983). The ETS family is represented with 27 members in humans, with 26 in the mouse, 
with ten in Caenorabtitis elegans (C.elegans) and with nine in Drosophila (Kar & Gutierrez-
Hartmann, 2013). ETS proteins function as the nuclear effectors of multiple signaling path-
ways, thereby regulating a variety of processes. The activity of many ETS proteins is regulat-
ed by post-translational modifications including phosphorylation, acetylation and sumoy-
lation. The most prominent modification is phosphorylation by mitogen activated protein ki-
nases (MAPKs); these can either control the downstream activity, subcellular localization or 
protein partners of ETS factors (Yordy & Muise-Helmericks, 2000).  
 
1.2.1.1 The ETS domain 
 
The DNA binding domain, called the ETS-domain, is the common characteristic shared by all 
proteins that belong to this family of transcription factors. The ETS-domain is a variant of the 
winged helix-turn-helix-structure with three alpha-helices and four anti-parallel beta-sheets 
and binds to a core 5' - GGA(A/T) - 3' DNA sequence (Hollenhorst et al, 2011). Despite bind-
ing to similar sequences on the DNA, ETS proteins are involved in many different biological 
processes including regulation of cell proliferation, inhibition of apoptosis, promotion of dif-
ferentiation, regulation of neuronal functions, cell migration and angiogenesis and they there-
fore regulate a corresponding number of target genes. Binding specificity and diversity are 
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likely achieved by collaborating with other transcription factors and/or co-regulatory proteins, 
or by restricted expression to a certain tissue (Hollenhorst et al, 2011). There is some redun-
dancy in function as assessed by genetic knockouts and genome-wide studies on promoter 
occupancy (Zhang et al, 2009; Hollenhorst et al, 2007). In addition, many ETS proteins are 
expressed ubiquitously in several cell types. In some cases, up to 25 family members can be 
co-expressed in the same cell type (Hollenhorst et al, 2004; Galang et al, 2004). 
The ETS-domain proteins are classified in 11 families (ETS, ERG, ELG, ELF, ESE, ERF, 
ETV, PEA3, SPI, TCF and PDEF) based on sequence similarity and the presence of further 
functional domains (Fig. 3) (Kar & Gutierrez-Hartmann, 2013). The majority of ETS proteins 
act as activators, only members of the ERF and ETV subfamilies repress transcription. A few 
other members, such as ELK-1 and NET, can do both, depending on the specific context and 
the interaction with other proteins (Sharrocks, 2001). NET, for example, switches from a re-
pressive to an activator function upon activation by Ras (Maira et al, 1996).  
 
               
 
Figure 3: Schematic structures of the human ETS subfamilies. Blue: the characteristic ETS DNA binding domain 
shared by all members. Orange: Pointed (PNT) domain found in about one-third of ETS factors. Green: B-box of 
the TCF family. Red: OST domain of the GABP family. P: known phosphorylation sites (adapted from Hollen-
horst et al., 2011 and Kar & Gutierrez-Hartmann, 2013).  
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1.2.1.2 The PNT domain 
 
In about one-third of ETS proteins (ETS, ETV, ERG families plus GABPα and SPDEF) a 
second functional domain is present, termed the Pointed (PNT) domain according to the name 
of the Drosophila ETS protein, in which it was first identified (Klämbt, 1993). The PNT do-
main is approximately 80 residues long and has a similar organization as the sterile alpha mo-
tif (SAM) domain that is known to engage in protein-protein or protein-RNA interactions 
(Qiao & Bowie, 2005). PNT domains have several functions:  
(1) as MAP kinase docking sites: the transcriptional activity of several ETS proteins (for ex-
ample ETS-1 and ETS-2, as well as the Drosophila ortholog Pnt-P2) is regulated by mitogen-
activated protein (MAP) kinase phosphorylation (Wasylyk et al, 1997). The PNT domain en-
hances binding of the ETS protein to the kinase thereby facilitating signaling. It is thought 
that docking of the PNT domain to the kinase enhances substrate specificity and the effective-
ness of phosphorylation (Sharrocks et al, 2000).  
(2) as a platform for interactions with other proteins: PNT domains not only serve as MAP 
kinase docking sites, but can also mediate the interaction with other proteins. In the case of 
ETS-2 the PNT domain is responsible for binding to the C-terminal domain of CREB-binding 
protein (Qiao & Bowie, 2005). 
(3) for self association: ETV-6 or its Drosophila homolog Aop form helical polymers via their 
PNT domains (Kim et al, 2001; Qiao et al, 2004). A dimer presumably facilitates DNA bind-
ing, but a longer polymer might also enable the recruitment of other protein partners. Other 
ETS proteins acquire a dimeric configuration as well, but typically not via the PNT but via 
their ETS domains (Cooper et al, 2014). 
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1.2.2 The Drosophila ETS family  
 
Drosophila melanogaster possesses eight ETS genes: pnt, anterior open (aop), Ets21C, Ecdy-
son induced protein 74EF (E74), Ets96B, Ets98B, Ets65A and Ets97D. pnt, aop, E74 and 
Ets97D have been characterized based on mutant alleles whereas Ets98B, Ets65A and Ets21C 
were cloned and sequenced based on fragments amplified with degenerated primers homolo-
gous to a region of the ETS domain of ETS-1 that is highly conserved (Chen et al, 1992; 
Pribyl et al, 1991, 1988; Lai & Rubin, 1992). The final Drosophila ETS protein, Ets96B, was 
identified through a BLAST search using the ETS domain of human ETS-1, PU-1 or SPI-1. 
With the exception of pnt and aop, all Drosophila ETS genes were named or renamed accord-
ing to their chromosomal position (Hsu & Schulz, 2000).  
 
Pnt and Aop play important roles in Drosophila eye development where they act as nuclear 
effectors of the Ras/MAP kinase pathway and provide an excellent example of the interplay 
between active and repressive functions of ETS proteins. In the absence of MAP kinase path-
way activity, Aop sits on the DNA by default and represses the expression of genes needed 
for photoreceptor cell determination. Pnt and Aop are both phosphorylated by the MAP ki-
nase Rolled (Rl) leading to the activation of Pnt and to the export of Aop from the nucleus 
(Brunner et al, 1994; O’Neill et al, 1994; Rebay & Rubin, 1995). The interplay between Pnt 
and Aop is not only important during eye development, but also to pattern the ventral ecto-
derm, for the migration of tracheal cells, and to activate the TGFβ homolog Decapentaplegic 
(Dpp) during dorsal closure (Metzger & Krasnow, 1999; Gabay et al, 1996; Noselli, 1998). 
 
In addition to pnt and aop, E74 and Ets97D also have been characterized by mutational stud-
ies. E74 is important during metamorphosis and is spliced into two isoforms; E74A and E74B. 
E74B mutants are unable to form normal pupae, they die either as early pupae or prepupae. In 
contrast, many E74A mutants survive the period as prepupaes and die before emerging from 
their cocoon (Fletcher & Thummel, 1995). E74 has also been reported to regulate apoptosis 
during metamorphosis by activating the apoptosis inducer Hid in the respective tissues (Jiang 
et al, 2000). 
Ets97D is required for the correct localization of oskar and gurken mRNA in the Drosophila 
oocyte and also for the migration of follicle cells. With the continuous enlargement of the 
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oocyte, the follicle cells migrate posteriorly until they surround the oocyte. This process is 
crucial to ensure proper development of the embryo. Ets97D has been implicated in these 
processes as its absence leads to small eggs and abnormal formation of the egg chamber 
(Schulz et al, 1993; Gajewski & Schulz, 1995) 
Functions for the remaining Drosophila ETS genes have mainly been deduced from expres-
sion patterns. Ets98B is broadly expressed in embryos, especially in the premigratory primor-
dial germ cells (PGC), but lost in the migratory and postmigratory PGCs. In addition, the gene 
is expressed in oocyte nuclei and larval tissues (Hsouna et al, 2004). Ets21C and Ets65A are 
both expressed throughout development. Around stage 12 and 14 of embryogenesis, their ex-
pression becomes restricted to the nervous system and they have therefore been hypothesized 
to play a role in the development of the central nervous system (CNS) (Chen et al, 1992). In 
addition, Ets21C has been implicated in regulating defense responses against pathogens, as 
Ets21C expression is induced upon activation of an immune response and Ets21C mutants 
also exhibit a higher load of bacteria (Boutros et al, 2002; Chambers et al, 2012; Radyuk et 
al, 2010). For Ets96B neither expression nor experimental data is available that would allow 
conclusions to be drawn about its function. 
Table 1: Overview of Drosophila ETS genes (modified from Hsu and Schulz, 2000). 
Gene Chromosomal position Human homolog Function 
pnt 3R 94E10-94E13 ETS-1 Eye development, oogenesis, tracheal 
cell migration 
aop 2L 22D1 ETV6 Eye development, tracheal cell mi-
gration, dorsal closure 
E74 3L 74D4-74E2 ELF2 Metamorphosis, wing development? 2 
 
Ets97D 3R 97D7 GABPα Oogenesis, wing development? 2 
 
Ets65A 3L 65A6 FLI-1 CNS development 1 
 
Ets98B 3R 98B2 PDEF/ESF Germ cell development1, wing devel-
opment? 2 
Ets21C 2L 21E2 ERG JNK signaling, neoplastic tumor 
growth 
Ets96B 
 
3R 96A22 ER81 Unknown 
 
1 Deduced from expression patterns (Chen et al, 1992). 2 Conclusions based on our own data described in 
Appendix 4.1. 
INTRODUCTION 
 
22 
1.2.3 ETS transcription factors and cancer 
 
Due to their crucial role as effectors of many signaling pathways, particularly the MAP kinase 
pathways, it is not unexpected that a dysfunction of ETS proteins can contribute to the devel-
opment of cancer. ETS protein mediated transformation can occur via several mechanisms; 
here we will only briefly describe the two most common mechanisms: Overexpression of ETS 
proteins and ETS gene fusions.  
 
1.2.3.1 Overexpression of ETS proteins 
 
ETS proteins are overexpressed in several solid cancers including breast, prostate, lung and 
colon as well as in leukemias. Breast cancers frequently show an upregulation of the ETS 
proteins, ESE-1, PEA3, ETS-1, ETS-2, ERM or ER81 and this is usually associated with a 
poor prognosis and metastasis as they regulate the expression of a number of genes that sup-
port tumorigenesis such as MMP genes, VEGF, BCL2 or HER2 (Seth & Watson, 2005; 
Turner et al, 2007). Expression of PEA3 subfamily members (PEA3, ERM, ER81) correlates 
with HER2 expression in 25-30% of HER2-positive breast cancers. PEA3 expression is con-
trolled by HER2 via MAPK pathway activation and in turn stimulates HER2 expression via a 
positive feedback loop (Benz et al, 1997; Scott et al, 1994). Similar to PEA3, overexpression 
of ETS-1 promotes metastasis and invasiveness of breast cancer by affecting the expression of 
urokinase (uPA), MMP1, MMP3 or vimentin (Dittmer, 2003).  
Advanced stage prostate cancer is another type of solid cancer that is associated with either 
overexpression of ETS factors such as ETS-1, ETS-2, FLI-1, ERG, ESE-2, ELF-1 or ETV-1, 
or downregulation of other ETS protein like PEA-3, PDEF or ESE-3 (Alipov et al, 2005; 
Cangemi et al, 2008; Gu et al, 2007; Rostad et al, 2007). It is not well understood why ETS 
proteins are differentially regulated in this cancer. 
Besides solid cancers, ERG is upregulated in acute myeloid leukemia (AML) and associated 
with a poor prognosis (Baldus et al, 2004; Marcucci et al, 2005). Until a correlation between 
ERG and WNT1 expression was recently found, only little was known about downstream 
targets of ERG that would promote leukemogenesis. ERG and WNT1 are co-expressed in 
80% of AML cases analyzed and a knockdown of ERG lead to a downregulation of WNT1 
transcripts (Mochmann et al, 2011). 
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1.2.3.2 ETS fusion proteins 
 
Another mechanism of ETS dependent oncogenesis involves ETS gene fusions; this frequent-
ly occurs in prostate cancers, Ewing`s sarcoma and leukemias. In prostate cancers, 5` 
TMPRSS2 can be fused to ERG, ER81 or PEA3. The TMPRSS:ERG fusion is the most abun-
dant one, found in 50% of prostate cancers. TMPRSS is an androgen-responsive gene and the 
fusion to ETS genes results in androgen-dependent activation of ETS target genes that support 
cellular transformation and invasive characteristics such as MYC misexpression (Sun et al, 
2008; Tomlins et al, 2008) 
Another type of cancer that is often associated with ETS gene translocations are Ewing`s sar-
comas. In the majority of cases, 5`EWS is fused to the 3` end of FLI1, resulting in a much 
stronger transactivator than FLI1 itself (Riggi & Stamenkovic, 2007). NROB1/DAX1 is a di-
rect transcriptional target of EWS-FLI1 and an important mediator of oncogenesis as a deple-
tion of DAX1 in EWS-FLI1 cells lines results in growth arrest (Kinsey et al, 2009; García-
Aragoncillo et al, 2008). The tumor suppressor FOXO1 is directly repressed by EWS-FLI1, 
and probably also contributes to tumor formation (Kar & Gutierrez-Hartmann, 2013). Often, 
pathogenesis of EWS-FLI1 depends on cooperativity with other transcription factors that have 
binding sites close to those of EWS-FLI (Kim et al, 2006).  
The third type of cancer that often harbors ETS genes translocations are leukemias. A single 
ETS gene, TEL, is engaged in more than 40 different types of translocations found in hemato-
logical cancers. Common fusion partners are AML1, or kinases such PDGFRB, TRK, ABL or 
JAK2  
(Romana et al, 1995; Golub et al, 1994, 1996; Papadopoulos et al, 1995; Lacronique et al, 
1997). If the fusion partner is a tyrosine kinase, oligomerization of the PNT domain of TEL 
causes a constitutive activation of the kinases, which promotes transformation and pathogene-
sis (Kar & Gutierrez-Hartmann, 2013). In case of AML1, the TEL-AML1 fusion protein ac-
quires an exclusively repressive function and prevents differentiation (Hiebert et al, 1996). 
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1.3  Aims of the project  
  
The project presented here is based on previous work performed in our laboratory (Master 
Thesis J. Toggweiler). RasV12 dlgRNAi tumors were transcriptionally profiled with microarrays 
to compare the gene expression levels of wild-type and RasV12 dlgRNAi cells. We identified 
over 500 misregulated genes. Based on their fold change we selected 100 of the upregulated 
genes and tested if a depletion of the gene product by RNAi modified  the tumor phenotype. 
As the tumors express GFP we could easily score tumor size by looking at GFP expression 
under a fluorescent binocular. In this way, we narrowed down the selected candidates to ten 
genes that strongly suppressed growth of RasV12 dlgRNAi tumors upon depletion of the gene 
product. We further validated these results by quantifying tumor size more accurately and 
confirmed the upregulation of these genes in RasV12 dlgRNAi cells with quantitative real-time 
PCR (qRT-PCR). Interestingly, eight of the ten suppressors did not show a phenotype in wild-
type eye discs suggesting that their growth regulatory effects are specific for the tumor.  
 
As aim of this thesis we wanted to carry out a detailed functional characterization of two of 
the identified suppressors. We chose two candidates that showed a strong suppression of tu-
mor growth, but had no effect on wild-type eye imaginal discs: Ets21C and astrocytic leucin-
rich repeat molecule (Alrm). Ets21C is a member of the Drosophila ETS family of transcrip-
tion factor in Drosophila and was considered interesting due to the relevance of ETS proteins 
in cancer (see section 1.2.3). The second candidate has not been characterized extensively. In 
the following sections, we will present our characterization of these two genes, including our 
work to understand how they regulate tumor growth. A last section will present a study about 
Grindelwald (Grnd), a newly identified Drosophila tumor necrosis factor receptor (TNFR) 
homolog, to which we contributed. 
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2 Results and Discussion 
 
This thesis investigates growth regulatory mechanisms in RasV12 dlgRNAi tumors. We identified 
and characterized new components that contribute to tumor growth.  
 
Section 2.1 is the main part of this thesis and comprises a study addressing the role of Ets21C 
in RasV12 dlgRNAi tumors. A depletion of Ets21C significantly decreased growth of RasV12 
dlgRNAi tumors whereas overexpression of Ets21C increased tumor growth. Ets21C expression 
is elevated in tumors and is regulated by the JNK pathway. Moreover, Ets21C activates JNK 
pathway target genes that induce and sustain tumor growth, possibly via interaction with the 
transcription factor AP-1. Additional subsections describe supplemental experiments that ad-
dress the following topics: effects of an Ets21C depletion or overexpression on RasV12 or 
dlgRNAi tumors; occupancy of Mmp1 regulatory regions by Ets21C; requirement of a potential 
phosphorylation site for Ets21C function; structure function analysis of Ets21C; mutagenesis 
of AP-1 sites in the regulatory region of Ets21C.  
 
Section 2.2 delineates experiments directed at elucidating the role of alrm, in neoplastic tu-
mors. Alrm is specifically upregulated in RasV12 dlgRNAi tumors and a depletion of Alrm sup-
presses tumor growth. Furthermore, we started to investigate a connection between Alrm and 
the JNK pathway as we had evidence that Alrm might interact with an adaptor protein that 
links the JNK pathway receptor to further downstream components. An additional subsection 
provides an outlook of future experiments to dissect the role of Alrm in neoplastic tumors.  
 
Section 2.3 presents a publication that describes the discovery of Grnd as the receptor for the 
Drosophila TNF-α homolog Egr: Egr activates the JNK pathway via Grnd. Furthermore, 
Grnd associates with apical polarity determinants, providing a link between loss of polarity 
and neoplastic tumor growth.  
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2.1  Ets21C regulates neoplastic growth by cooperating with AP-1 
 
The following study focused on functionally characterizing the role of the Drosophila ETS 
transcription factor, Ets21C, in tumor growth. RNAi mediated depletion of Ets21C strongly 
suppressed RasV12 dlgRNAi dependent tumor growth. The expression or activity of human ETS 
proteins is frequently deregulated in several types of cancers and therefore elucidating the role 
of Ets21C in RasV12 dlgRNAi tumors could provide new insights into the mechanisms of ETS 
factor mediated transformation. In subsequent experiments, we have generated a mutant allele 
of Ets21C and confirmed the results obtained with the RNAi. As the molecular function of 
Ets21C was not well defined, we worked to identify the pathway that regulates Ets21C ex-
pression as well as target genes that are induced upon Ets21C. Our current working model is 
that Ets21C associates with the AP-1 transcription factor to activate target genes required for 
tumor growth. 
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ABSTRACT 
 
The JNK pathway is crucial for coordinating and transducing cellular responses to stress. Be-
longing to the MAPK family, its role is conserved across species. While upstream factors of 
the pathway are well established, the transcriptional control of target genes is less well under-
stood. Neoplastic tumors in Drosophila heavily depend on JNK signaling to induce target 
genes that are essential for tumor growth and invasion. In this study we identified the tran-
scription factor Ets21C as a pivotal regulator of tumor growth: depletion strongly suppressed 
growth while ectopic expression of Ets21C increased tumor size. In addition, we find that 
Ets21C expression is elevated as a consequence of JNK signaling activity. In turn, the JNK 
pathway transcription factor AP-1 requires Ets21C to induce target genes that drive tumor 
growth. Furthermore, we demonstrate that the Ets21C DNA-binding domain and the Pointed 
domain are essential for Ets21C function. Our data reveal Ets21C as a novel player in regulat-
ing the transcriptional program of the JNK pathway and thus improve our understanding of 
the mechanisms that govern tumor growth.  
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INTRODUCTION 
 
Cells have to constantly adapt to changes in their environment. This is achieved via sophisti-
cated intracellular signaling pathways that integrate and amplify signals from various extra-
cellular stimuli to regulate cellular processes such as proliferation, apoptosis or differentia-
tion. The Jun N-terminal kinase (JNK) pathway is a subgroup of the mitogen-activated protein 
(MAP) kinase signaling pathways and is responsible for activating the apoptotic machinery in 
response to inflammatory cytokines or environmental stress such as UV radiation, heat or 
reactive oxygen species (Weston & Davis, 2007). Defects in JNK signaling are associated 
with several pathologies such as neurological disorders, type 2 diabetes or cancer. Mammals 
possess three Jnk genes, Jnk1, Jnk2 and Jnk3, all of which can be spliced into different 
isoforms (Davies & Tournier, 2012). In contrast, Drosophila has only one JNK and thus rep-
resents a simpler system, which facilitates genetic analyses and the identification of pathway 
components. In flies, stress cues also lead to JNK pathway activation. One such cue is Eiger 
(Egr), the Drosophila tumor necrosis factor (TNF) homolog (Moreno et al, 2002; Igaki et al, 
2002). Binding of Egr to the TNF receptor Grindelwald (Grnd) recruits several adaptor pro-
teins that lead to the phosphorylation of TGF-β activated kinase 1 (TAK1) (Andersen et al, 
2015; Takatsu et al, 2000). Consequently, dTAK1 activates the JNKK Hemipterous (Hep) 
that activates the JNK Basket (Bsk) (Riesgo-Escovar et al, 1996; Sluss et al, 1996; Glise et al, 
1995). Finally, Bsk phosphorylates the transcription factors Jun and Fos (Jra and Kayak in 
Drosophila), which dimerize to form the activator protein 1 (AP-1) complex that induces 
transcription of target genes (Kockel et al, 2001). puckered (puc) is one of these target genes 
and encodes a negative regulator of the JNK pathway that dephosphorylates Bsk (Martín-
Blanco et al, 1998). While the upstream components of the JNK pathway in Drosophila are 
well known, it is less clear how different target genes are activated in different contexts and if 
AP-1 requires co-factors for such transcriptional activation. 
 
Neoplastic tumors serve as a valuable system in Drosophila to study the JNK pathway as their 
cells exhibit JNK signaling activity without undergoing apoptosis (Igaki et al, 2006; Uhlirova 
& Bohmann, 2006; Andersen et al, 2015). These tumors are generated by concomitantly acti-
vating Ras signaling (RasV12) and inactivating scribbled (scrib): if Drosophila eye imaginal 
discs are genetically manipulated in such way, large tumors form that invade neighboring 
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tissues such as the ventral nerve cord (VNC) and the brain lobes (Brumby & Richardson, 
2003; Pagliarini, 2003). Scrib is required to establish and maintain apical-basal polarity and 
forms a complex with two other proteins, Discs-large (Dlg) and Lethal giant larvae (Lgl) 
(Bilder & Perrimon, 2000; Bilder, 2000). If scrib-/- cells grow as clones among wild-type 
cells, however, they are eliminated from the tissue via JNK signaling (Igaki et al, 2006). Loss 
of polarity is thought to activate the JNK pathway through association of apical polarity de-
terminants with the TNF receptor Grnd (Andersen et al, 2015). The activation of Ras in scrib-
/- cells renders them resistant to cell death, as Ras activity favors proliferation and cell surviv-
al, resulting in cells that continue to proliferate in an uncontrolled manner (Brumby & 
Richardson, 2003). In this context, activation of the JNK pathway induces the expression of 
Matrix metalloproteinase 1 (Mmp1), which leads to the degradation of extracellular matrix 
proteins, thereby allowing tumor cells to become mobile and to migrate out of their tissue of 
origin (Uhlirova and Bohmann, 2006). JNK signaling also upregulates the expression of the 
cytokines Unpaired1 (Upd1), Unpaired2 (Upd2) and Unpaired3 (Upd3). Upd1 and Upd2 
stimulate cell growth and proliferation by activating JAK/STAT signaling (Wu et al., 2010).  
 
In this study we used a modified version of the above described RasV12 scrib-/- tumor model to 
identify factors that are required for tumor growth. We identified the transcription factor 
Ets21C as a crucial regulator of tumor growth: depletion of Ets21C strongly suppressed tumor 
growth while ectopic expression increased tumor size. Ets21C expression was found to be 
elevated in tumor cells and this upregulation is a consequence of JNK signaling activity. In 
turn, Ets21C associates with AP-1 and stimulates the expression of downstream effectors that 
increase tumor growth.  
 
 
RESULTS AND DISCUSSION – ETS21C  
 
31 
RESULTS 
 
RasV12 dlgRNAi tumors require Ets21C for growth  
 
To identify genes that regulate growth of RasV12 scrib-/- tumors, we used a modified assay that 
employs a dsRNA targeting dlg instead of mutations in scrib. This system can accommodate 
all genetic components necessary to cause a neoplastic phenotype in one fly stock and makes 
it possible to test the effect of additional transgenes (RNAi, or cDNA constructs) in a one 
generation cross (Willecke et al, 2011). To identify new components that regulate tumor 
growth, we tested a subset of genes that were upregulated in RasV12 dlgRNAi tumors by RNAi 
and screened for modifications of the tumor phenotype. We identified an RNAi targeting the 
Ets21C (CG2914) transcript as a strong suppressor of tumor growth (Fig. 1). Tumors depleted 
of Ets21C are reduced to half the size of control tumors, which in turn lead to an increased 
fraction of larvae that succeeded to pupariate (Fig. 1, A, B and K). Typically, only a subset of 
larvae bearing control tumors manage to pupariate while most die as larvae (Fig. 1, L). De-
pleting tumors for Ets21C results in an increased 'pupae to dead larvae' ratio (Fig. 1, L). To 
exclude the possibility that the growth suppressing effects are caused by off-target activities 
of the RNAi transgene, we created a null allele of the Ets21C gene by inducing a deletion that 
removed a major part of the gene (Fig. 1, G and H). As the deletion is homozygous lethal, we 
used the MARCM system to generate clones homozygous mutant for Ets21C and expressing 
RasV12 and dlgRNAi. Similar to the effects of the Ets21CRNAi, deleting Ets21C leads to a reduc-
tion of tumor size and to a significant restoration of disc morphology (Fig. 1, G and H). 
 
As removal of Ets21C exhibited tumor growth suppressing effects, we wondered whether 
higher levels of Ets21C would promote growth of RasV12 dlgRNAi tumors. Co-expression of 
HA-tagged Ets21C (Ets21CHA) together with RasV12 and dlgRNAi did indeed increase tumor 
size and shifted the lethality point to earlier stages, i.e. more animals died as larvae (Fig.1, A, 
C, K and L). 
 
Complementary to our data from eye imaginal discs, we found that changes in Ets21C levels 
also affected the growth of wing disc tumors (Sup. Fig.1, B-C). In this assay, we targeted ex-
pression of the respective transgenes to the posterior compartment of the wing disc by means 
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of an engrailed-Gal4 driver (Willecke et al, 2011). RasV12 dlgRNAi expression leads to over-
growth of the posterior compartment resulting in a much larger wing disc and in lethality of 
the animal (Sup. Fig. 1, A and B). Co-expression of Ets21CRNAi partially restricted overgrowth 
of the wing disc whereas expression of the Ets21CHA protein further enlarged the posterior 
compartment at the expense of the anterior part (Sup. Fig. 1, B-D). In sum, these results 
demonstrate that Ets21C regulates growth of RasV12 dlgRNAi tumors in both eye and wing disc 
tissue. 
 
To assess whether Ets21C generally affects growth or only exhibits an effect on tumor cells, 
we depleted or overexpressed Ets21C in wild-type cells (Fig. 1, D-F). Interestingly, the effect 
on proliferation of wild-type cells was different compared to tumors. Wild-type eye discs ex-
pressing Ets21CRNAi were slightly enlarged (Fig. 1, D and E), but developed into morphologi-
cally normal adult eyes (Sup. Fig. 2, D and E). In addition, Ets21C mutant clones did not be-
have differently from wild-type clones (Fig. 1, I and J). In contrast, overexpression of Ets21C 
leads to loss of imaginal disc tissue and triggered apoptosis as evidenced by the presence of 
active Caspase 3 (Cas3) (Fig. 1, D and F, Sup. Fig. 2, A-C). Consistent with this effect, the 
adult eye and head were smaller than wild-type (Sup. Fig 2, D and F). This phenotype was 
partially rescued by co-expression of Drosophila inhibitor of apoptosis protein 1 (DIAP1) 
(Sup. Fig. 2, G). Taken together, these results suggest that depletion of Ets21C exhibits a high 
degree of tumor-specificity, while overexpression causes an effect in wild-type animals that is 
opposite to that observed in tumor backgrounds.  
 
Depletion of other ETS proteins does not negatively influence tumor growth 
 
Ets21C belongs to the family of ETS (E-twenty six) transcription factors, which is unique to 
metazoans and represented by eight members in Drosophila. The Drosophila ETS proteins 
have been implicated in various processes such a oogenesis, metamorphosis, eye development 
and cell migration (Hsu & Schulz, 2000). The best characterized Drosophila ETS proteins are 
Pointed (Pnt) and Anterior open (Aop). Pnt is a transcriptional activator downstream of the 
Ras/MAPK pathway and Aop acts as repressor of MAPK target genes. Upon MAPK pathway 
activation, Aop is phosphorylated and inactivated, which releases target genes from repres-
sion. Concomitantly, Pnt is phosphorylated and activated by MAPK and stimulates transcrip-
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tion of target genes (Brunner et al, 1994; O’Neill et al, 1994; Rebay & Rubin, 1995). In 
mammals, different ETS family members are known to interact with each other or with co-
regulatory protein partners to control gene expression (Oikawa & Yamada, 2003). We rea-
soned that depleting Ets21C could abrogate a vital association with another Drosophila ETS 
protein and thereby elicit the observed tumor suppressing effect. Particularly Pnt or Aop 
would be good candidates to serve as Etc21C partners, as they act downstream of Ras signal-
ing (Brunner et al, 1994; O’Neill et al, 1994). In order to test this assumption, we analyzed 
the effect of knocking-down pnt and aop in the tumor background. All RNAi constructs effi-
ciently downregulated the expression of their corresponding genes (Ets21C, pnt or aop, Fig. 
2, F). In contrast to Ets21C, however, downregulation of pnt or aop expression did not cause 
growth suppressing effects on tumors (Fig. 2, A- E). Tumors expressing an RNAi targeting 
pnt were even increased in size (Fig. 2, A, C and E). 
 
We also tested the role of the other five Drosophila ETS genes in tumor growth, Ets97D, 
Ets98B, Ets65A, Ets96B and E74. None of these genes affected tumor growth upon depletion 
(Sup. Fig. 3, A-G). This was not unexpected as Ets98B, Ets65A and Ets96B are expressed at 
very low levels in RasV12 dlgRNAi tumors and Ets97D and E74 have been implicated in differ-
ent processes (Sup. Fig. 3, H7) (Hsu & Schulz, 2000). From these results, we conclude that 
Ets21C is the only Drosophila ETS protein required for growth of RasV12 dlgRNAi tumors. 
 
Ets21C expression depends on the JNK pathway  
 
Growth of RasV12 dlgRNAi tumors is regulated by downstream effects of RasV12, which can lead 
to MAPK or PI3K activation, and loss of polarity, which results in JNK pathway activation 
(Igaki et al, 2006; Willecke et al, 2011). Transcriptome profiles of RasV12 dlgRNAi tumors have 
revealed an upregulation of Ets21C; we reasoned that its expression could be regulated either 
by the MAPK/PI3K or by the JNK pathway. To test this, we co-expressed different JNK 
pathway components with RasV12 and examined Ets21C expression levels (Fig. 3, A). First, 
we co-expressed RasV12 and Egr, the Drosophila TNF-α homolog and a strong activator of the 
JNK pathway, in eye imaginal discs and measured Ets21C expression levels by qPCR. Strik-
ingly, we observed a 30-fold upregulation of Ets21C transcript levels in RasV12 UAS-egr tu-
mors, a response even stronger than that observed in RasV12 dlgRNAi tumors (Fig. 3, B). Ex-
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pression of the Mmp1 gene, an established JNK pathway target (Uhlirova & Bohmann, 2006), 
was also strongly induced (Fig. 3, C). Next we combined RasV12 with core JNK components 
acting downstream of Egr: the Drosophila JNK Basket (Bsk) and the JNKK Hemipterous 
(Hep). Bsk and Hep expression also induced expression of Ets21C and Mmp1 (Fig. 3, D and 
E). To complement these findings, we also blocked JNK signaling in RasV12 dlgRNAi tumors 
using RNAi targeting the JNK transcription factors Jun or Fos and monitored Ets21C expres-
sion. Consistent with our previous data, Ets21C and Mmp1 levels decreased upon removal of 
Jun or Fos (Fig. 3, F-I). We therefore conclude that Ets21C expression in neoplastic tumors is 
dependent on the JNK pathway. 
 
Since Ras is constitutively active in all the experimental conditions we exploited, it leaves 
open the possibility that Ras signaling, via MAPK or PI3K activation, is required in conjunc-
tion with JNK pathway activity for the observed Ets21C upregulation. To test this, we activat-
ed the JNK pathway in wild-type eye discs by expressing Egr in the Glass-Multimer-Reporter 
(GMR) expression domain and measured Ets21C transcript levels by qPCR. Similar to our 
observations in the tumor background, Ets21C as well as the control target Mmp1 are strongly 
induced upon Egr expression in the absence of a RasV12. Therefore, JNK pathway activity is 
sufficient to induce Ets21C expression independent of elevated Ras activity (Fig. 3, J and K). 
 
Ets21C influences the expression of JNK pathway targets  
 
Having established that Ets21C expression is regulated by the JNK pathway, we wanted to 
investigate, which genes are activated downstream of Ets21C in the tumor context. To this 
end, we analyzed and compared the transcriptomes of RasV12 dlgRNAi tumors co-expressing 
either Ets21CRNAi or Ets21CHA. We identified 24 genes that were significantly downregulated 
upon Ets21C depletion and upregulated if Ets21C was overexpressed (Sup. Fig. 4, A). Among 
these genes was Mmp1, a known JNK pathway target (Uhlirova & Bohmann, 2006). Deple-
tion of Ets21C in RasV12 dlgRNAi tumors decreased Mmp1 expression whereas overexpression 
of Ets21C increased Mmp1 levels (Fig. 4, A). In agreement with our qPCR results, we found 
that Mmp1 expression is reduced at the protein level if Ets21C is depleted in RasV12 dlgRNAi 
tumors (Fig. 4, B). 
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In addition to Mmp1, two genes that are downstream of JNK signaling were also found differ-
entially expressed in the microarray analysis: upd1, and PDGF and VEGF related factor 
1(Pvf1) (Sup. Fig. 4, A). However, in contrast to Mmp1, it is not known whether upd1 or Pvf1 
activation through the JNK pathway is direct or indirect. upd1 encodes a cytokine that acti-
vates the JAK/STAT pathway. It has previously been found to be upregulated in RasV12 scrib-
/- tumors in a JNK-dependent manner and to be essential for tumor growth (Wu et al, 2010). 
Pvf1 is one of the Drosophila orthologs of mammalian vascular endothelial growth factors 
(VEGFs) and platelet derived growth factors (PDGFs) and known to drive hemocyte prolifer-
ation in neoplastic tumors (Parisi et al, 2014). qPCR analysis confirmed the differential ex-
pression of upd1 and Pvf1 upon altering Ets21C levels (Fig. 4, C). Moreover, we found that 
other Upd- and PDGF/VEGF-like factors (Upd2, Upd3, Pvf2 and Pvf3) were also significant-
ly upregulated in tumors overexpressing Ets21C (Sup. Fig. 4, B). Thus, our results show that 
Ets21C regulates the expression of various critical targets of the JNK pathway, targets that 
explain, at least in part, the effects Ets21C exerts on tumor growth. 
 
We next asked if the ability of Ets21C to induce Mmp1, Pvf1 and upd1 expression was de-
pendent on the RasV12 dlgRNAi background or if it was a general function of Ets21C. In order to 
test this, we measured transcript levels of Mmp1, Pvf1 and upd1 in wild-type eye discs over-
expressing Ets21C and in discs that co-expressed RasV12 and Ets21C. As in RasV12 dlgRNAi 
tumors, expression of Ets21C in RasV12 tumors or wild-type eye discs lead to an induction of 
Mmp1 and Pvf1 transcripts and to a lesser extent also upd1 transcripts (Fig. 4, D and E). This 
indicates that Ets21C is able to activate these target genes in a physiological context.  
 
The ETS and PNT domains are essential for Ets21C function  
 
ETS proteins share as their unifying domain an ETS DNA binding motif, a variant of the 
winged helix-turn-helix motif that not only mediates binding to the DNA, but can also medi-
ate protein-protein interactions (Sharrocks, 2001). Besides the DNA binding domain, about 
one third of ETS proteins encompasses the Pointed (PNT) domain that has originally been 
identified in the Drosophila ETS protein Pnt (Klämbt, 1993). PNT domains have been shown 
to govern homo-oligomerization, hetero-dimerization as well as transcriptional repression 
(Qiao & Bowie, 2005). A SMART alignment for Ets21C revealed that, besides the common 
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ETS DNA binding domain, Ets21C also harbors a PNT domain (Schultz et al, 1998). In order 
to gain insights into which part of Ets21C accounts for its effects on tumor growth, we gener-
ated protein variants that lack either the ETS or the PNT domain and tested their effects on 
RasV12 dlgRNAi tumors (Fig. 6, A-E). Deleting the DNA binding domain (Ets21CΔEts) abrogated 
the tumor growth enhancing effect that we observed with full length Ets21C. It even caused a 
slight dominant-negative effect as tumors expressing Ets21CΔEts were smaller than control 
tumors (Fig. 6, B, C and E). Ets21C without the PNT domain behaved like Ets21CΔEts: these 
tumors were also smaller than control tumors (Fig. 6, D). In addition, we performed qPCR on 
RNA isolated from tumor cells expressing the protein variants and monitored the expression 
of the Ets21C targets Mmp1, Pvf1 and upd1. Consistent with the effects on tumor growth, 
expression of Mmp1, Pvf1 and upd1 did not increase upon expression of Ets21CΔEts or 
Ets21CΔPnt and remained at the same levels as in control tumors or were even slightly de-
creased (Fig. 6, F and G).  
Taken together, our results demonstrate that the function of Ets21C depends on both, the ETS 
and the PNT domains.  
 
Effects of Ets21C depend on JNK signaling  
 
Given the requirement of the DNA binding domain for Ets21C function and taking into ac-
count that the genes induced by Ets21C are known to be targets of the JNK pathway, we 
sought to clarify the relationship between Ets21C and JNK signaling regarding target gene 
induction. Ets21C could act either downstream of AP-1 or together with AP-1. For Pvf1 and 
upd1 it is not known whether they are directly or indirectly activated by the JNK pathway. 
Mmp1 is a direct target as its expression is mediated by AP-1 binding sites in its regulatory 
region; we hypothesized that Ets21C and AP-1 may co-operatively activate target gene ex-
pression (Uhlirova & Bohmann, 2006). To investigate this possibility, we first checked 
whether Ets21C outputs genetically depend on the JNK pathway. To this end, we co-
expressed a dominant-negative form of Bsk (BskDN), the Drosophila Jun kinase, together with 
RasV12, dlgRNAi and Ets21CHA and monitored Mmp1, Pvf1 and upd1 expression. Blocking the 
JNK pathway abrogated expression of all three genes regardless of whether or not Ets21CHA 
was overexpressed (Fig. 6, A). This change was also reflected in a dramatic reduction of tu-
mor size upon BskDN expression. We observed a similar effect when we inhibited JNK signal-
RESULTS AND DISCUSSION – ETS21C  
 
37 
ing at the level of the two AP-1 transcription factors, Jun and Fos: depletion of both together 
reverted the expression levels of Mmp1, Pvf1 and upd1 induced by Ets21CHA to those found 
without Ets21C overexpression (Fig. 6, B). These results show that Ets21C-dependent up-
regulation of Mmp1, Pvf1 and upd1 requires JNK signaling activity. Importantly, Pvf1 and 
upd1 upregulation is not an indirect downstream consequence of JNK signaling mediated by 
Ets21C. Hence we conclude that Ets21C likely co-operates with AP-1 to mediate maximal 
target gene expression. 
 
To gain further insight into the mechanism underlying this cooperation we performed co-
immunoprecipitation experiments with Ets21C and/or Jun or Fos proteins to test for a physi-
cal interaction between the three proteins. It is well documented that Jun and Fos bind to each 
other, but it is not known to which extent they depend on additional co-factors to drive target 
gene expression. We found that N-terminally HA-tagged Ets21C precipitates C-terminally 
FLAG-tagged Jun or Fos from Drosophila Kc167 cell lysates (Fig. 6, C). While Jun and Fos 
were readily detectable, we did not find GFP in the precipitates, which emphasizes the speci-
ficity of the interaction. Thus, our genetic and biochemical data suggest that the function of 
Ets21C depends on a direct cooperation with AP-1. 
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DISCUSSION 
 
In this study, we used a genetic approach to identify novel genes that regulate growth of 
RasV12 dlgRNAi tumors. We identified the transcription factor Ets21C as a regulator of tumor 
growth and found its gene to be a target of the JNK pathway. Moreover, we uncovered a nov-
el role for Ets21C as a potential co-factor of AP-1; together, these DNA-binding factors drive 
the expression of specific target genes that induce and sustain growth and invasiveness of 
RasV12 dlgRNAi tumors.  
 
Neoplastic tumors depend on Ets21C function 
 
The human ETS gene family comprises 28 genes that affect a wide range of cellular processes 
such as proliferation, apoptosis, differentiation, migration and invasion. Defective or hyperac-
tive ETS proteins substantially contribute to several diseases, among them cancer (Kar & 
Gutierrez-Hartmann, 2013). Here, we demonstrate that RasV12 dlgRNAi tumors require Ets21C 
function: tumors depleted for Ets21C remained small and showed a reduced expression of key 
factors that drive tumor malignancy. Overexpression of Ets21C increased tumor size and tar-
get gene expression, underscoring that Ets21C is not only required for tumor growth, but also 
capable of enhancing tumor malignancy. Studies on human ETS factors corroborate these 
findings as the closest human orthologs of Ets21C, ETS-related gene (ERG) and Friend leu-
kemia virus-induced erythroleukemia 1 (FLI-1) have been linked to tumorigenesis as well 
(Chen et al, 1992). ERG is fused to Transmembrane protease, serine 2 (TMPRSS ) in 50% of 
prostate cancers, which results in androgen mediated activation of ERG. Another type of can-
cer in which fusion of ERG is frequently observed is Ewing sarcoma, a soft tissue cancer oc-
curring in children. In these tumors, ERG and FLI-1 can be fused to the EWS gene turning the 
resulting products into more potent transactivators than ERG or FLI-1 on their own. Besides 
chromosomal translocations, ERG is overexpressed in acute myeloid leukemia (AML) and is 
associated with a poor prognosis, whereas higher FLI-1 expression has been detected in triple 
negative breast cancer or in metastatic melanoma (Li et al, 2014; Kar & Gutierrez-Hartmann, 
2013).  
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Ets21C is a context-independent target of the JNK pathway 
 
While RasV12 dlgRNAi tumors depleted for Ets21C are smaller than control tumors, wild-type 
tissue is not affected by the loss of Ets21C. This suggests that Ets21C function might only be 
required if a tissue has to cope with stress such as increased growth and epithelial disorgani-
zation in RasV12 dlgRNAi tumors, but is otherwise dispensable. Such a role for Ets21C is sup-
ported by previous reports that analyzed Ets21C mutant flies challenged with pathogens. 
Chambers et al. (2012) demonstrated that Ets21C mutants are more susceptible to infection 
with certain pathogens, either due to a reduced tolerance or to a higher bacterial load 
(Chambers et al, 2012; Ayres et al, 2008). Additional studies identified Ets21C transcripts 
among the immediate early response genes activated in immune challenged cells or flies. Im-
portantly, this activation depends on the JNK pathway as it is blocked in tak1 or hep mutants, 
but not in cells mutant for the Immune deficiency (IMD) pathway components relish (rel) and 
kenny (key) (Boutros et al, 2002; Johansson et al, 2005; Radyuk et al, 2010). 
 
Loss of epithelial polarity caused by a depletion of dlg activates the JNK pathway that criti-
cally affects tumor growth. Since we found elevated Ets21C transcript levels in RasV12 dlgRNAi 
tumors we tested whether Ets21C expression was induced as a consequence of JNK signaling. 
Indeed, Ets21C is highly upregulated if we directly activate the JNK pathway in RasV12 tu-
mors by co-expressing Egr. Conversely, Ets21C expression is prevented in RasV12 dlgRNAi tu-
mors if we block the formation of the JNK transcription factor AP-1 by removing one of its 
components, Jun or Fos. In addition, we found that Ets21C is induced in response to JNK 
signaling in a wild-type background implying that Ets21C expression also depends on JNK 
pathway activity in a non-neoplasia context.  
 
Although Ets21C is activated by the JNK pathway in both tumor and wild-type tissues, its 
effects vary greatly. Ectopic expression in tumors increases growth, while it causes cell death 
in a wild-type background. This paradoxical result can be explained with the presence or ab-
sence of RasV12 and the role of Ets21C in the JNK pathway. Previous studies have shown that 
polarity deficient cells are eliminated from the tissue in a JNK-dependent manner (Brumby & 
Richardson, 2003). Removal of these cells is, however, prevented if RasV12 is present 
(Brumby & Richardson, 2003; Pagliarini, 2003). In a RasV12 background the same mechanism 
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likely protects Ets21C expressing cells from undergoing apoptosis and unleashes its potential 
in driving tumor growth.  
 
Importantly, while this manuscript was in preparation, Külshammer et al. (2015) published 
related findings, which also suggest that Ets21C functions downstream of the JNK pathway, 
and acts as an oncogene in cooperation with Ras; we consider this as an independent valida-
tion of certain aspects of our study (Kulshammer et al, 2015). 
 
Ets21C cooperates with AP-1 in inducing tumor growth  
 
A unifying feature of ETS transcription factors is their DNA binding domain that recognizes a 
core sequence 5'-GGA(A/T)-3'. With all ETS proteins sharing the same core binding motif, 
specificity for target gene activation must be governed by protein sequences flanking the ETS 
domain, but also by cooperation with other transcription factors and co-activators (Cooper et 
al, 2014). Protein-protein interactions can occur directly on the DNA via the ETS domains, or 
via the PNT domains, a second functional domain present in about 30% of ETS proteins. Our 
analyses on Ets21C demonstrate that both, the ETS and the PNT domain are relevant for 
Ets21C function. Protein variants lacking the ETS or the PNT domain do not increase tumor 
growth if co-expressed with RasV12 dlgRNAi nor do they upregulate Mmp1, Pvf1 and upd1 ex-
pression. 
 
Mmp1, Pvf1 and upd1 expression has previously been shown to be induced by the JNK path-
way and to be essential for tumor growth and invasion (Uhlirova & Bohmann, 2006; Wu et al, 
2010; Parisi et al, 2014). Based on this data, we wondered if and how Ets21C regulates tran-
scriptional outputs of the JNK pathway. (1) Ets21C could interact with Jun and/or Fos. (2) 
Ets21C could activate or interact with an unknown factor that feeds back on the JNK path-
way. We show here that in RasV12 dlgRNAi tumors the effects of Ets21C fully depend on an 
active JNK pathway. If the latter is blocked by co-expressing BskDN with RasV12 dlgRNAi and 
Ets21CHA, tumors remain small and there is no induction of the target genes Mmp1, Pvf1 or 
upd1. These results support both possibilities (1 and 2), but exclude an autonomous function 
of Ets21C. A physical interaction between Ets21C and Jun and Fos has previously been pro-
posed based on large scale mass-spectroscopy data (Rhee et al, 2014). Here, we show in cul-
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tured cells that HA-tagged Ets21C binds FLAG-tagged Jun or Fos, suggesting that the three 
proteins interact to regulate target gene expression. Such a model is further supported by stud-
ies in mammalian systems that have shown a physical interaction between AP-1 and the 
Ets21C ortholog ERG, or other ETS proteins (Bassuk & Leiden, 1995; Camuzeaux et al, 
2005; Basuyaux et al, 1997).  
 
Based on our data we propose a two-step model on how JNK signaling regulates tumor 
growth: in an early wave of pathway activity AP-1 induces the expression of targets such as 
cell death genes, puc, Ets21C and likely additional targets that remain elusive. In a wild-type 
background, this leads to apoptosis as demonstrated by numerous studies (Moreno et al, 2002; 
Luo et al, 2007; Brumby & Richardson, 2003; Takatsu et al, 2000). Neoplastic tumors, how-
ever, are protected against cell death through the presence of RasV12, which allows the induc-
tion of a second tier of targets, such as Mmp1, Pvf1 and upd1. Importantly, these targets not 
only depend on AP-1 activity, but also on Ets21C as their expression is reduced in tumors 
depleted for Ets21C (Fig. 6, D). So far we can, however, not distinguish whether Ets21C only 
enhances and sustains AP-1 dependent target gene expression or whether it is required for 
their initial activation. In conclusion, our results provide a novel mechanistic explanation for 
the role of Ets21C in tumorigenesis. 
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MATERIALS & METHODS 
Fly stocks and genetics 
 
To test for an effect on tumor growth, UAS-RNAi lines or UAS-cDNAs were crossed to fe-
males of the following tester fly stock: eyFlp; UAS-RasV12, UAS-dlgRNAi(VDRC41134), UAS-
GFP/CyO, tub-Gal80BL9491; act>CD2>Gal4, UAS-GFPS65T. To express the transgenes in a 
wild-type background, the following flies were used: eyFlp; sp/CyO; act>CD2>Gal4, UAS-
GFPS65T. To generate tumors that express RasV12 only, we used: eyFlp; act>y+>Gal4, UAS-
GFP/CyO, tub-Gal80BL9491; UAS-RasV12/TM6b flies. yw flies were used for control crosses. 
To generate MARCM clones, eyFlp; FRT40, tub-Gal80/SM5; tub-Gal4, UAS-GFP/TM6b 
females were crossed to yw; FRT40; MKRS/TM6b or yw; FRT40, ΔEts21C21/SM5; +/TM6b 
or yw; FRT40; UAS-RasV12, UAS-dlgRNAi(BL34854)/TM6b or yw; FRT40, ΔEts21C21/SM5; UAS-
RasV12, UAS-dlgRNAi(BL34854)/TM6b males. Flies and larvae were reared and kept at 25°C. Other 
RNAi lines from the Vienna Drosophila RNAi library (VDRC) used were: UAS-Ets21CRNAi 
(51225), UAS-Ets65ARNAi(15354), UAS-dJunRNAi(107997), UAS-rempARNAi(31575), UAS-
rempARNAi(103424). From the DGRC TripRNAi: UAS-FosRNAi(BL33379), UAS-PntRNAi(BL35038), UAS-
AopRNAi(BL35404), UAS-Ets97DRNAi(35749), UAS-Ets98BRNAi(36811), UAS-Ets96BRNAi(BL31935), UAS-
E74RNAi(BL29353). The following fly stocks used for overexpression experiments were from 
FlyORF: UAS-Ets21CHA(F000624), UAS-JraHA(F000089), UAS-kayHA(F001841). Other fly stocks used 
were: UAS-egr (Moreno et al. 2002), UAS-hepBL9308, UAS-bskBL9310, UAS-Diap1 (from G. 
Halder), GMR-Gal4 (Hay et al, 1994). 
To generate tumors in the posterior compartment of wings discs, yw; UAS-RasV12, UAS-
dlgRNAi(VDRC41134)/SM5; +/TM6b or yw; UAS-RasV12, UAS-dlgRNAi(VDRC41134), UAS-
Ets21CRNAi(VDRC51225)  or yw; UAS-RasV12, UAS-dlgRNAi(VDRC41134)/SM5; Ets21CHA(F000624)/TM6b 
males were crossed to females of the following genotype: yw; en-Gal4, Gal80ts, UAS-CD8-
GFP/CyO; MKRS/TM6b females. yw flies were used as control. The progeny was kept at 
18°C for 120 h and then transferred to 29°C for 48h. 
 
Quantification of tumor volume 
 
Tumor bearing larvae were dissected 6-7 days after egg laying (AEL). For confocal imaging 
and quantifications, larvae were fixed according to standard protocols and tumors were 
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mounted in VectaShield (Vector Laboratories). To minimize squeezing of tumors by the cov-
er slip, one layer of double scotch tape was placed between cover slip and glass slide. Image 
stacks were treshholded for GFP and analyzed with Icy to calculate the tumor volume (de 
Chaumont et al, 2012). When GFP intensities were quantified from whole larvae, tresholding 
in ImageJ was used to detect and measure GFP signal only in the head parts of the animals.  
 
Cloning and generation of transgenes 
 
Truncated proteins: A plasmid with the open-reading frame of the Ets21C A isoform was 
obtained from FlyORF. To produce the Ets21C protein variants, overlapping PCRs were per-
formed to either delete aminoacids 134-214 (ΔPnt) or 254-339 (ΔEts). The truncated protein 
versions were cloned into pUAST.attB via Acc65I and XbaI cut sites that had been attached 
in the PCR. With the same cloning strategy, a wild-type version of Ets21C without HA-tag 
was cloned as well to exclude any adverse effects of the HA tag. All constructs were inserted 
via the ΦC31 integrase system into landing site ZH-86Fb (Bischof et al, 2007). 
Expression vectors for cell culture: fos or Ets21C cDNA was amplified by PCR and inserted 
into the triple HA-containing vector pMZ55 via NheI and XbaI sites. The fragments were 
then subcloned along with the HA-tag into pUAST via Acc65I and XbaI sites.  
 
Generation of the Ets21C deletion 
 
Ets21C was removed with an in trans recombination of flanking PiggyBac (PBac) elements 
according to the strategy of Parks et al. (Parks et al, 2004). PBac elements WH Ets21Cf03639  
and RB rempAe02928 were combined with hsp70-flp on the X-chromosome and then brought 
together in trans. hsFlp; Ets21Cf03639/ rempAe02928 progeny were heat-shocked two days AEL 
for 1h at 37°C. The heat-shock was repeated the next two days. Single adult males were 
crossed to balancer stocks and the progeny was tested by PCR for recombination with one 
primer binding to the remaining part of WH Ets21Cf03639 going in direction of the RB element 
and another primer binding to the flanking region of the RB element going in direction of the 
WH element. A product is only yielded if recombination was successful as the region between 
the primer binding sites is otherwise too long. The recombination also removed a part of the 
neighboring gene rempA (CG11838). However, mutant clones do not show any obvious phe-
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notypes (Fig. 1, I and J) and expression of an RNAi targeting rempA in RasV12 dlgRNAi cells 
did not have an effect on tumor growth (Sup. Fig. 4, C).  
 
Immunofluorescence 
 
Fixation and immunostainings of Drosophila eye imaginal discs and tumors were performed 
according to standard protocols. Primary antibodies used in this study were: anti-Mmp1 
(1/200, 3B8D12, Developmental studies hybridoma bank (DSHB)) and anti-DE-cadherin 
(1/200, DCAD2, DSHB). Alexa fluor 594 (1/500, Molecular Probes) was used as label for the 
secondary antibody. Imaginal discs were mounted in VectaShield (Vector Laboratories). Im-
ages were taken with a Zeiss Lsm710 confocal microscope and processed with ImageJ and 
Adobe Photoshop.  
 
RNA isolation and real-time PCR 
 
For RNA isolations, larvae were dissected in Ringers plus 0.05% Tween-20 and tumors were 
collected in an 1.5 ml Eppendorf tube. Tumors were centrifuged for 10 min at 4°C and pellets 
were snap freezed in liquid nitrogen, stored at -80°C or processed further. For each experi-
ment total RNA was isolated from 30 tumors or 45 wild-type eye discs with the indicated 
genotypes using the NucleoSpin RNA kit (Machery Nagel). Following an additional Dnase 
digest for 1h at 37°C (DNA-freeTM kit, Ambion), 500 ng of total RNA was used for cDNA 
synthesis with the transcriptor High Fidelity cDNA Synthesis Kit (Roche) using oligo-dT 
primers. Quantitative PCR reactions were performed in triplicates using the MESA Green 
qPCR Mastermix Plus for SYBR Assay (Eurogentec) and an ABI Prism SDS 7900 HT (Ap-
plied Biosystems). All mesurements of transcript levels were normalized to actin-5C, alpha-
tubulin and TATA box binding protein (TBP). Primers were designed with Roche Universal 
Probe Library or with Primer3plus. When ever possible an intron-spanning assay was chosen. 
Primers used were: Ets21C: F: caacgacgacgaaccaaat, R: gttcgcgttggacgaatc, Mmp1: F: 
gaaggctcggacaacgagt, R: gtcgttggactggtgatcg, Pvf1: F: aagccggaacaccattgac, R: 
catgatgctgcgcttaaagt, Upd: F: gcacactgatttcgatacgg, R: ctgccgtggtgctgtttt, actin: F: gcccatctac-
gagggttatgc, R: aatcgcgaccagccagatc, alpha-tubulin at 84C: F: gccagatgccgtctgacaa, R: ag-
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tctcgctgaagaaggtgttga, TATA binding protein: F: cgcgcatcatccaaaagc, R: gccgaccatgtttt-
gaatcttaa 
 
Microarrays  
 
Total RNA was isolated and Dnase digested as described above from tumors with the follow-
ing genotypes: eyFlp; UAS-RasV12, UAS-dlgRNAi/+; act<CD2<Gal4, UAS-GFP/+ or eyFlp; 
UAS-RasV12, UAS-dlgRNAi/UAS-Ets21CRNAi; act<CD2<Gal4, UAS-GFP/+or eyFlp; UAS-
RasV12, UAS-dlgRNAi/sp or CyO; act<CD2<Gal4, UAS-GFP/UAS-Ets21CHA. RNA was sent to 
the Genomics platform in Geneva (http://www.ige3.unige.ch/genomics-platform.php) for fur-
ther processing and hybridization to Affymetrix GeneChip arrays for Drosophila. Microarray 
data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under acces-
sion number E-MTAB-4315. 
 
Drosophila cell culture and transfections 
 
Kc167 cells were cultured in M3+PYRE medium supplemented with 5% FBS and 1% peni-
cillin/streptomycin at 25°C. Cells were transfected with expression vectors using 
FuGene®HD (Promega) according to the manufacturers protocol. 
 
Immunoprecipitation and western blotting 
 
Kc167 cells (2 x 106 cells per well) were seeded into a 6-well plate and transfected with the 
indicated expression vectors. UAS-GFP was used as control for transfection efficiency and to 
keep the total amount of DNA transfected constant. Cells were harvested 48 h post-
transfection and lysed in lysis buffer containing 20mM Tris-HCl pH 7.5, 1.5mM MgCl2, 
75mM NaCl, 1mM EGTA, 5% Glycerol, 0.25% Nonidet P-40 and protease inhibitors (Com-
plete Mini, Roche). Following 5 min of sonication with a Bioruptor, the cell suspension was 
centrifuged at full speed at 4°C and supernatants were mixed with 30μl of Protein A se-
pharose beads (GE Healthcare) and 1μg of HA antibody (sc-805, Santa Cruz) and allowed to 
rotate for 4 h at 4°C. Beads were collected (2500 x g, 3 min at 4°C), washed 2 x with lysis 
buffer and stored at -20°C until further processing.  
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For western blot analysis, protein complexes were eluted from the beads, denatured and re-
solved on 4-12% NuPAGE Bis-Tris gels (Invitrogen) and transferred to a PVDF membrane 
(Amersham Hybond-P, GE Healthcare). After blocking with 5% milk, the membrane was 
incubated with either anti-FLAG M2 (mouse, 1/2000, Sigma) antibody followed by secondary 
goat anti-mouse antibodies conjugated with horseradish peroxidase (1/5000, Jackson Labora-
tories). Signals were detected with Western Bright Quantum detection reagent (Advansta). 
After stripping (Re-Blot Plus Strong Solution, Millipore), membranes were blocked and incu-
bated with anti-HA (mouse, 1/2000, HA.11, Covance) antibody. 
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FIGURE LEGENDS 
 
Figure 1: RasV12 dlgRNAi tumors are sensitive to changes in Ets21C expression. Confocal 
images of (A-C) imaginal disc tumors and (D-F) wild-type imaginal discs expressing different 
UAS-transgenes under the control of eye specific Gal4: Flp recombinase is driven by the eye-
less (ey) promoter, and causes activation of the act>y+>Gal4 transgene. Recombined cells are 
marked by expression of a UAS-GFP transgene (green). In (D-F) DNA is stained with DAPI 
(blue). The discs co-express the following transgenes: (A) RasV12, dlgRNAi, (B) RasV12, dlgRNAi, 
Ets21CRNAi, (C) RasV12, dlgRNAi, Ets21CHA, (D) none, (E) Ets21CRNAi, (F) Ets21CHA. Discs (G-
I) contain ey-FLP induced MARCM clones (Lee & Luo, 1999) that are positively labeled 
with GFP (green). Additionally, discs are stained for E-cadherin (E-cad) to visualize cell out-
lines (magenta). (G) RasV12 dlgRNAi expressed in wild-type clones, (H) RasV12 dlgRNAi expressed 
in clones homozygous mutant for Ets21C, (I) wild-type clones, (J) clones homozygous mutant 
for Ets21C. (K) Quantification of tumor volume for the genotypes indicated (Mann-Whitney 
test **** p<0.0001) Error bars indicate SD. (L) Ratio between number of pupae and larvae 
for the genotypes indicated. Depleting Ets21C increased the number of pupae compared to 
control tumors whereas overexpressing Ets21C lead to a decrease of larvae undergoing pupar-
ation. (A) and (C) are composites of several images to display the whole tumor size. Scale 
bars: (A-F) 200μm, (G-J) 100μm. 
 
Figure 2: Knockdown of pnt or aop does not affect tumor growth 
(A-D) Images of whole larvae carrying RasV12 dlgRNAi tumors in eye discs depleted for 
Ets21C, Pnt or Aop. Tumor cells are marked by the expression of a GFP transgene (green). 
Tumors express the following additional transgenes: (A) none, (B) Ets21CRNAi (C) pntRNAi, (D) 
aopRNAi. (E) Quantification of fluorescence intensity. Larvae were 6-7 days old (t- test **** p-
value < 0.0001, * p-value <0.05, ns p-value = 0.65). (F-H) qRT-PCRs for Ets21C, pnt or aop 
to assess the efficiency of RNA knockdown. Error bars indicate SD. 
 
Figure 3: The JNK pathway regulates Ets21C expression 
(A) Schematic overview of relevant components of the JNK signaling pathway. (B) (D), (F) 
and (G): qRT-PCR quantification of Ets21C mRNA from dissected tumors with the indicated 
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genotypes. (C), (E), (H) and (I): qRT-PCR for Mmp1 mRNA from dissected tumors with the 
indicated genotypes. Ets21C is strongly upregulated in response to Eiger (B) or the JNK 
pathway components Hep and Bsk (D). Upregulation of Ets21C in RasV12 dlgRNAi tumors is 
blocked if Jun (F) or Fos (G) is removed. Similar results were observed for the established 
JNK pathway target Mmp1 (C), (E), (H) and (I). (K) and (L) qRT-PCRs for Ets21C or Mmp1 
of eye discs that express Egr in the GMR expression domain indicating that the Ets21C and 
Mmp1 genes are also activated by the JNK pathway in a wild-type situation. Error bars indi-
cate SD. 
 
Figure 4: Ets21C influences the expression of JNK pathway targets  
(A) Levels of Mmp1 transcripts were reduced upon Ets21C depletion and increased if Ets21C 
was overexpressed in RasV12 dlgRNAi (RDi) tumors. (B) Confocal images of RasV12 dlgRNAi tu-
mors with the indicated genotypes. Tumor cells express GFP and are stained for Mmp1 (red) 
and DAPI (blue). Mmp1 protein levels change in a similar way as Mmp1 transcripts upon 
Ets21C depletion or overexpression. (C) qRT-PCRs to detect Pvf1 and upd1 transcripts of 
dissected tumors with the indicated genotypes. Pvf1 and upd1 are differentially expressed 
upon changes in Ets21C levels (D) and (E) Mmp1, Pvf1 and upd1 transcripts were also upreg-
ulated in RasV12 tumors (D) or wild-type eye discs (E) overexpressing Ets21C. Scale bar: 
100μm. Error bars indicate SD. 
 
Figure 5: The DNA binding and PNT domains are essential for Ets21C function  
(A) Schematic overview of the wild-type Ets21C protein structure and the truncated versions 
generated. (B-E) Confocal images of RasV12 dlgRNAi (RDi) tumors expressing different UAS-
transgene versions of Ets21C under the control of a FLP-inducible Gal4 driver. Flp recom-
binase is under the control of the eyeless promoter that is active in eye discs. Flp recombined 
cells are marked by expression of a UAS-GFP transgene (green). (B) Control, (C) Ets21Cwt, 
(D) Ets21CΔPnt and (E) Ets21CΔEts. Ets21C protein variants lacking the DNA binding domain 
(ΔEts) (F) or the PNT domain (ΔPnt) (G) were no longer able to induce Mmp1, Pvf1 and upd1 
expression. Error bars indicate SD. (B) and (C) are composites of several images to display 
the whole tumor size. Scale bar: 100μm. 
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Figure 6: Ets21C cooperates with the JNK pathway to activate target genes 
(A) Blocking the JNK pathway by expressing BskDN in RasV12 dlgRNAi (RDi) tumors that over-
express Ets21C abrogates the induction of Mmp1, Pvf1 and upd1 expression. (B) A similar 
effect is observed if the JNK pathway is blocked by knocking down Jun and Fos. Error bars 
indicate SD. (C) Ets21C physically interacts with Jun (second lane) or Fos (third lane). Kc167 
cells were transfected with the transgenes indicated, together with tub-Gal4 and dTak1 to ac-
tivate the JNK pathway. Anti-HA immunoprecipiates were immunoblotted first with anti-
FLAG or anti-GFP antibodies (part of the blot below 35kDa). GFP was used as a negative 
control. After stripping, the same blot was incubated with anti-HA antibodies. (D) Model of 
Ets21C action: Ets21C is expressed in response to JNK pathway activation as a consequence 
of loss of polarity. Once Ets21C is expressed, it associates with AP-1 and together they drive 
the expression of target genes critical for tumor growth and invasion. 
 
Fig. S1: Ets21C phenotypes are recapitulated in wing disc tumors 
(A-C) Third instar wing discs expressing different transgenes in the posterior compartment by 
means of en-Gal4. Discs are stained for E-cad (blue) and co-express GFP (green) and the fol-
lowing transgenes: (A) RasV12, dlgRNAi , (B) RasV12, dlgRNAi, Ets21CRNAi, (C) RasV12, dlgRNAi, 
Ets21CHA. Similar to eye discs, wing disc tumors are suppressed upon Ets21C knockdown, 
but enhanced if Ets21C is overexpressed. Scale bar: 100μm. 
 
Fig. S2: Ets21C causes apoptosis in a wild-type background  
 (A-C) Confocal images of wild-type eye imaginal discs expressing GFP (green) and stained 
for DAPI (blue) and cleaved Caspase 3 (Cas3, red) (A`-C`). (A) Control eye disc, (B) Disc 
expressing Ets21CHA, (C) close-up of the boxed region in (B). (D-F) Images of adult eyes 
expressing the indicated transgenes. Ets21C induces apoptosis as evident by an increase in 
Cas3 activation (B and C). This phenotype is partially rescued by co-expression of Diap1 (F). 
Scale bar: 100μm.  
 
Fig. S3: A knockdown of other ETS family members does not affect tumor growth 
(A-F) Images of whole larvae carrying RasV12 dlgRNAi tumors in eye discs depleted for Ets97D, 
Ets98B, Ets96B, Ets65A or E74. Tumor cells are marked by the expression of a GFP 
transgene (green). (G) Quantification of fluorescence intensity. Larvae were 6-7 days old (t- 
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test, ns: non-significant). (H) Expression levels of Drosophila ETS family members in RasV12 
dlgRNAi tumors. Data were obtained from three independent microarrays. Error bars indicate 
SD. 
 
Fig. S4: Gene expression change upon Ets21C overexpression or depletion. 
(A) 24 genes that are significantly (fold change >2) upregulated upon Ets21C overexpression 
and downregulated with Ets21CRNAi in RasV12 dlgRNAi tumors (RDi). (B) Differential expres-
sion of additional Pvfs and Upd cytokine genes upon changes in Ets21C levels. (C) RNAi 
targeting rempA does not affect tumor growth. Images of whole larvae are shown carrying 
either control RasV12 dlgRNAi tumors or tumors depleted for RempA. 
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Figure 6 
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RESULTS AND DISCUSSION – ETS21C  
 
65 
2.1.1 Ets21C is able to partially substitute for the loss of polarity in tumors 
 
To further investigate the role of Ets21C in neoplastic tumors, we asked whether modifica-
tions of Ets21C levels had an impact on discs expressing only RasV12 or dlgRNAi. To test this, 
we generated RasV12 or dlgRNAi expressing tumors with the same system as for the RasV12 dlgR-
NAi tumors. RasV12 tumors overgrew to a similar extent as RasV12 dlgRNAi tumors, but they 
stayed as a two dimensional layer in contrast to RasV12 dlgRNAi tumors that grow in three di-
mensions (Fig. 4, A). Eye discs expressing a dlgRNAi develop into small neoplastic tumors that 
resemble dlg mutant eye discs (Fig. 4, D) (Bilder, 2000). Interestingly, co-expression of 
RasV12 and Ets21CHA induced three dimensional growth and a slight increase in tumor size, 
but not to the same extent as the combination of RasV12 and dlgRNAi (Fig. 4, C). Depletion of 
Ets21C did not have any obvious effects on RasV12 tumors (Fig. 4, B). Yet, combined with the 
dlgRNAi, Ets21CRNAi seemed to partially restore shape and structure of the eye disc (Fig. 4, E, 
arrow). In contrast, overexpression of Ets21C together with the dlgRNAi strongly reduced the 
size of dlgRNAi tumors, reminiscent of its effects in a wild-type background (Fig. 4, F and Fig. 
1, F). Taken together, these results suggest that Ets21C is partly sufficient to induce neo-
plastic growth in combination with RasV12 and that its depletion it is able to ameliorate the 
phenotype of dlgRNAi tumors. Particularly the effect on dlgRNAi tumors is interesting and further 
supports our hypothesis that Ets21C is required to drive JNK pathway outputs. However, for a 
more detailed confirmation, we would need to generate dlgRNAi tumors in an Ets21C mutant 
background and test if tumor development can be blocked from the onset. 
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2.1.2 Ets21C occupies ETS binding sites in the Mmp1 promoter 
 
We have shown that Ets21C induces the expression of Mmp1 and other target genes down-
stream of the JNK pathway. Furthermore, we could demonstrate that the DNA binding do-
main of Ets21C is required for target gene induction and that Ets21C can physically interact 
with the JNK transcription factor AP-1, making it likely that Ets21C directly activates these 
targets. In order to demonstrate binding of Ets21C to the regulatory regions of Mmp1, we per-
formed chromatin-immunoprecipitations (ChIP) of RasV12 dlgRNAi tumors that co-expressed 
Ets21CHA followed by qPCR of putative Mmp1 regulatory regions. We designed five primer 
pairs over a stretch of about 7000 bp upstream of the translational start site that contained 
 
 
Figure 4: Effects of Ets21C depletion and overexpression on RasV12 and dlgRNAi tumors. (A) - (C) Confocal 
images of control RasV12 tumors (A) or RasV12 tumors expressing Ets21CRNAi (B) or Ets21CHA (C). Ets21CHA 
seems to enhance growth of RasV12 tumors. (D) – (F) Confocal images of control dlgRNAi tumors (D) or tumors 
co-expressing Ets21CRNAi (E) or Ets21CHA (F). Tumors express GFP (green) and are stained for DAPI (blue). 
A depletion of Ets21C partially inhibits the effects of the  dlgRNAi as more wild-type looking structures re-
appear (arrow). In contrast, overexpression of Ets21C results in much smaller dlgRNAi tumors. Scale bar: 100 
μm. 
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consensus Ets21C and/or AP-1 binding sites (Fig. 5, A). The primer pair that was located 
7000 bp away from the translational start site served as a control pair, where we would not 
expect to find an enrichment of Ets21C. We also made sure that the amplicons covered the 
four putative AP-1 sites that, based on reporter studies, had previously been shown to regulate 
Mmp1 expression (Uhlirova & Bohmann, 2006). Due to the very small amounts of DNA that 
were recovered after the ChIP, we have only performed one successful qPCR run, but these 
preliminary results are very promising. Two primer pairs that covered a region with several 
AP-1 and two Ets21C binding sites showed a 20 fold enrichment of Ets21C at these sites, 
compared to the control primer pair (Fig. 5, B and C). Although we have to repeat this exper-
iment to reach meaningful conclusions, the results strongly hint towards binding of Ets21C at 
Mmp1 regulatory regions. In addition, it will be important to extend these studies to the regu-
latory regions of the two other targets, Pvf1 and upd1 (see Fig. 4 and Fig. 5 of section 2.1). If 
Ets21C also binds directly here our model would be strengthened. 
 
 
 
Figure 5: Enrichment of Ets21C at Mmp1 regulatory regions. (A) Schematic overview of the Mmp1 locus. 
Note that the region upstream of the translational start has been streched in length to better visualize the PCR 
amplicons (red lines Nr. 5 – Nr. 10). (B) and (C) qPCRs of Ets21C ChIP and input samples with the primer 
pairs indicated. Results are shown as % input (B) and as fold enrichment relative to the control primer pair Nr. 
10 (C). 
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2.1.3 Ets21C activity is not regulated by phosphorylation on a consensus MAPK motif 
 
A common theme among ETS proteins is the regulation of their activity via post-translational 
modifications. Those comprise phosphorylation, glycosylation, sumoylation, acetylation and 
ubiquitination. Phosphorylation is the most frequent modification found and in the majority of 
cases is executed by MAP kinases. The activities of two Drosophila ETS proteins, Pnt and 
Aop, crucially depend on phosphorylation by MAPK. We therefore wondered whether 
Ets21C activity was also dependent on phosphorylation. MAPKs phosphorylate threonine or 
serine residues that occur in the motif P/LXT/SP (X can be any amino acid). Ets21C contains 
a consensus MAPK phosphorylation motif (PVTP) close to the C-terminus. In addition, it 
contains a PNT domain that, besides other functions, is known to serve as sites for MAPK- 
mediated phosphorylation; in the case of human ETS-1 the PNT domain provides a docking 
site for ERK2 (Seidel, 2002). To test if Ets21C activity depends on phosphorylation of the 
potential MAPK motif identified, we generated a protein variant in which we replaced threo-
nine 468 with alanine (Ets21CT468A). As described earlier, overexpression of Ets21C in RasV12 
dlgRNAi tumors leads to an enlargement of tumor size (Fig. 6, A). When we expressed the mu-
tant Ets21CT468A, tumors grew to the same size as when we expressed wild-type Ets21C (Fig. 
6, A and B). Similar result were also obtained in wild-type eye imaginal discs. Ets21CT468A 
caused the same phenotype as Ets21CWT (Fig. 6, C and D). From these results we conclude 
that Ets21C function is not critically regulated by phosphorylation at this site. We can, how-
ever, not exclude that Ets21C is phosphorylated on a different, atypical MAPK sites or by 
another kinase that recognizes a different motif.  
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2.1.4 Removing a part of Ets21C close to the N-terminus enhances its transcriptional 
activity 
 
When we generated the protein variants that lack the ETS or the PNT domain (see manuscript 
Figure 5), we also generated a variant that is lacking a part close to the N-terminus 
(Ets21CΔSOCS) that, based on SMART, has previously been annotated as a suppressor of cyto-
kine signaling (SOCS) domain known from human SOCS4 and SOCS5. SOCS proteins are 
known to regulate JAK/STAT signaling (Stec & Zeidler, 2011). Because JAK/STAT signal-
                
 
Figure 6: Ets21C is not phosphorylated at position 468. (A) and (B) Confocal images of RasV12 dlgRNAi tu-
mors co-expressing Ets21Cwt (A) or Ets21CT468A(B). Images of adult eyes expressing Ets21Cwt or 
Ets21CT468A. Tumors express GFP (green) and are stained for DAPI (blue). (A) and (B) are composites of 
several images to display the whole tumor size. Scale bar: 100 μm. 
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ing is relevant to RasV12 dlgRNAi tumors, we aimed to analyse the function of the SOCS domain 
(Wu et al, 2010). However, at present the same region of the protein is only annotated as a 
region of low complexity and a direct alignment with the respective domains of SOCS4 and 
SOCS5 did show an obvious conservation (data not shown). Nevertheless, we still thought it 
might be interesting to see if this part of the protein is important for the function of Ets21C. 
Interestingly, the variant lacking the “SOCS” domain even more strongly induced target 
genes compared to full-length Ets21C (Fig. 7, D) and also enhanced tumor growth further 
(Fig. 7, A-C). The above results leave several possibilities open regarding the function of the 
“SOCS” domain, it could function as repressive domain, provide a platform for interactions 
with a transcriptional repressor or be subject to post-translational modifications. Further ex-
periments will be necessary to distinguish between these possibilites. 
 
                   
 
Figure 7: The N-terminal part of Ets21C restricts its activity. (A) - (C) Confocal images of control RasV12 
dlgRNAi tumors (A) or tumors co-expressing Ets21Cwt (B) or Ets21CΔSOCS (C). Ets21CΔSOCS caused larger tu-
mors than Ets21Cwt and also increased expression of Mmp1, Pvf1 and upd1 as assessed by qPCR (D). Tumors 
express GFP (green). (B) and (C) are composites of several images to display the whole tumor size. Scale bar: 
100 μm.  
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2.1.5 Mutagenesis of AP-1 binding sites in the Ets21C regulatory region 
 
We and others have genetically shown that Ets21C expression is regulated by the JNK path-
way, but no one has provided evidence for a direct binding of the JNK transcription factor 
AP-1 to the regulatory region of Ets21C (Boutros et al, 2002; Kulshammer et al, 2015). A 
careful investigation of this issue is especially important, as a very recent study proposed that 
Ets21C expression is regulated by EGFR/Ras signaling (Jin et al, 2015). AP-1 recognizes a 
core consensus motif of 5`- T(G/T)AGTCA(C/T) - 3` as determined by bacterial-one hybrid 
assays (Zhu et al, 2011). We identified four AP-1 consensus binding sites in the Ets21C regu-
latory region (Fig. 8, A). To test if these sites are required for Ets21C expression, we isolated 
the Ets21C gene region including upstream and downstream sequences up to the neighboring 
genes and deleted the predicted AP-1 binding sites (Fig. 8, A and B, further referred to as 
Ets21CΔAP-1). We have previously generated an Ets21C null allele and found that growth of 
RasV12 dlgRNAi cells mutant for Ets21C is impaired (see Fig.1 section 2.1). To demonstrate that 
specific AP-1 sites govern Ets21C expression, we plan to express the wild-type Ets21C or 
Ets21CΔAP-1 in RasV12 dlgRNAi Ets21C-/- cells. If Ets21C expression depends on the presence of 
these specific AP-1 sites, we would expect that only wild-type Ets21C rescues the observed 
growth defects, but not Ets21CΔAP-1. Such a result would strongly hint towards binding of the 
Ets21C regulatory regions by AP-1. To further support this idea, we could try to identify the 
responsible AP-1 site, by deleting each of the four sites individually. A different, but com-
plementary approach would be to perform chromatin immunoprecipitations (ChIP) of AP-1 
either in RasV12 dlgRNAi tumors or wild-type cells with an active JNK pathway and test for an 
enrichment of Ets21C regulatory regions by qPCR. 
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2.1.6 Concluding remarks and future experiments 
 
This study demonstrates the process of evaluating and functionally characterizing a candidate 
gene retrieved from an RNAi screen. By combining genetic, molecular biology and biochemi-
cal techniques, we have successfully unravelled Ets21C function and established a model ex-
plaining how Ets21C can induce and sustain tumor growth. Besides the experiments described 
in 2.1.5 to demonstrate a direct regulation of Ets21C expression by AP-1, we can think of 
further points that could be investigated and that would strengthen our model of Ets21C ac-
tion:  
 
 
Figure 8: AP-1 binding sites in the Ets21C gene region. (A) Schematic representation of the Ets21C gene 
region. Red stars highlight consensus AP-1 binding motifs. (B) AP-1 binding motif as determined by bacte-
rial one-hybrid assays. 
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(1) Is Ets21C required for the initial induction on of Mmp1, Pvf1 and upd1 expression or does 
it only reinforce and sustain AP-1-dependent transcription?  
We have shown that a depletion of Ets21C reduces Mmp1, Pvf1 and upd1 expression levels as 
does a block of JNK signaling by expressing bskDN in RasV12 dlgRNAi tumors. However, we 
never directly compared the extent of transcript reduction between the two situations. As it is 
not possible to remove a gene product completely by RNAi, it would be better to measure 
Mmp1, Pvf1 and upd1 expression in Ets21C-/- mutant tumor cells and compare to expression 
levels of tumor cells that co-express bskDN. If target gene expression is entirely abolished in 
both cases, we could assume that Ets21C is necessary to initiate Mmp1, Pvf1 and upd1 ex-
pression.  
 
(2) Do AP-1 and Ets21C co-occupy regulatory regions of target genes? Although we have 
found a physical interaction between AP-1 and Ets21C, we do not know if and how they bind 
to regulatory regions of target genes. To answer this question we would need to generate 
ChIP-seq or ChIP-qPCR data for both transcription factors and show that they bind to the 
same DNA sequences. ChIP analyses demand a vast amount of starting material, which is 
difficult to collect from in vivo samples. We discuss solutions to this issue in a subsequent 
section (2.2.3.3) about immunoprecipitations followed by mass spectroscopy, where we 
would face a similar challenge.  
 
(3) Are both, Jun and Fos cooperating with Ets21C to drive target gene expression or only one 
of them? Despite having found a physical interaction between Ets21C and Jun and Fos, we do 
not know yet if Jun and Fos are both necessary to drive target gene expression. Since Jun and 
Fos can bind to each other, it is feasible that both associate with Ets21C by default, but only 
one of them is functionally important. We have tested such a scenario by co-expressing 
Ets21C and either an RNAi targeting jun or fos, but have obtained ambiguous results, most 
likely due to incomplete knockdown of the gene product (data not shown). To obtain more 
convincing data, we would need to generate RasV12 dlgRNAi tumors that overexpress Ets21C in 
a jun or fos mutant background. This is in principal possible, but will be genetically challeng-
ing. Dominant-negative alleles of Fos and Jun would be an alternative option as they might 
exert a stronger effect than RNAi, but are easier to combine with other transgenes than a mu-
tant allele.  
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(4) Which target genes activated by Ets21C are causing cell death in a wild-type background? 
We have identified Ets21C target genes that can explain its effects on RasV12 dlgRNAi tumors, 
but we have not elucidated yet, which Ets21C targets are causing apoptosis in a wild-type 
background. As they are important for tumor growth, we have tested whether overexpression 
of Mmp1, Pvf1 or Upd1 would cause a similar phenotype as Ets21C in wild-type eye disc, but 
we did not observe comparable effects (data not shown). Another gene that is strongly upreg-
ulated upon Ets21C expression and downregulated by the Ets21CRNAi is peptidoglycan recog-
nition protein SA (PGRP-SA). PGRP-SA usually recognizes bacterial particles and induces an 
immune response by activating the Toll pathway (Michel et al, 2001). The JNK pathway has 
been proposed to activate immune signaling pathways (Delaney et al, 2006). In eye imaginal 
discs it has been shown that the JNK pathway is provoking cell death directly by activating 
pro-apoptotic factors, but also indirectly by activating the Toll pathway, which induces apop-
tosis via an independent mechanism (Wu et al, 2015). As PGRP-SA is induced by Ets21C, we 
reasoned that this could lead to Toll pathway activation and ultimately cause cell death. To 
test this hypothesis, we have expressed Ets21C in flies heterozygous mutant for PGRP-SA. 
This combination leads to a less severe Ets21C overexpression phenotype, which would sup-
port our hypothesis (data not shown). However, we need to perform additional experiments 
before any conclusions can be drawn about a functional relationship between Ets21C and 
PGRP-SA.  
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2.2 Evaluation of Alrm as a potential regulator of tumor growth  
 
This part describes the characterization of astrocytic leucin-rich repeat module (alrm, 
CG11910), an additional suppressor that was retrieved from the initial RNAi screen. We also 
outline what follow up experiments could be done to further elucidate its function. We gener-
ated a deletion and an overexpression line for this gene and performed a few preliminary tests 
to determine how Alrm could affect tumor growth. Due to time constraints we decided to fo-
cus on analysing Ets21C and therefore stopped to work on Alrm. 
 
2.2.1 Background 
 
Alrm is a small gene lying in the intronic region of another gene, Fur1. The gene is usually 
expressed in a subtype of longitudinal glial cells that have recently been classified as Dro-
sophila astrocytes, but its molecular function is unknown (Stork et al, 2014).  
Interestingly, a former master student in the lab, George Busslinger, identified this gene in a 
screen for possible new components of the Drosophila TNF pathway. Egr is the Drosophila 
ortholog of mammalian TNF-α. Targeted expression of Egr in larval tissues activates the JNK 
pathway and causes apoptosis (Moreno et al, 2002; Igaki et al, 2002). Wengen (Wgn) was 
proposed to be the respective receptor for Egr. (Kanda et al, 2002). However, the evidence 
was inconclusive (see Section 2.3 for more information). In a yeast-two hybrid screen for ad-
ditional Egr pathway components, using DTRAF2 as bait, Alrm was found as an interaction 
partner. DTRAF2 is an adaptor protein that likely links the downstream kinases Misshapen 
(Msn) to the upstream TNF receptor (Liu et al, 1999). Yet, expression of a dsRNA targeting 
alrm in eye imaginal discs that were mutant for wgn and overexpressed Egr could not rescue 
the small eye phenotype caused by Egr induced apoptosis. Since RNAi rarely removes the 
gene product completely, it is possible that small amounts of Alrm are still enough to transmit 
the Egr signal. Since depletion of alrm suppressed RasV12 dlgRNAi tumors, we aimed to investi-
gate this phenotype more closely and to re-evaluate a role for Alrm in the activation of the 
JNK pathway. 
 
 
 
RESULTS AND DISCUSSION – ALRM 
 
76 
2.2.2 Results  
2.2.2.1 Alrm overexpression results in smaller tumors but does not affect normal tissue growth 
 
Alrm has been shown to be specifically upregulated in neoplastic tumors (Master Thesis J. 
Toggweiler). As a knockdown of alrm lead to smaller tumors, we asked whether overexpres-
sion of alrm would increase tumor size. To this end, we generated flies overexpressing alrm 
cDNA under UAS control. Surprisingly, extra Alrm also resulted in smaller tumors (Fig. 9. A-
C). This could be due to a dominant-negative effect of the overexpression. Such effects are 
often observed with overexpression constructs, especially if multiple proteins act in a com-
plex and the overexpressed protein might engage in non-functional complexes with some of 
the other components.  
Next, we asked whether the effects of knocking down or overexpressing alrm were specific 
for the tumors or whether it would also cause growth defects in a wild-type tissue. Wild-type 
eye imaginal discs depleted for alrm were growing normal and developed into a wild-type 
looking adult eye (Fig. 9, D and E). This was not unexpected as alrm expression is almost 
absent in wild-type discs (Master Thesis J. Toggweiler). Overexpression of Alrm also did not 
result in any obvious defects (Fig. 9, D and F). Taken together, these results suggest that alrm 
is not required for normal growth and development of eye imaginal disc tissue.  
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Figure 9: Phenotypes of an Alrm depletion or overexpression in neoplastic tumors and wild-type eye discs.  
(A) – (C) Confocal images of control RasV12 dlgRNAi tumors (A) or tumors co-expressing alrmRNAi (B) or alrm 
cDNA (C). (D) – (F) Images of wild-type Drosophila eyes (D) or eyes expressing an alrmRNAi (E) or alrm cDNA 
(F). Tumors express GFP (green). Depletion or overexpression of Alrm reduces tumor growth, but does not 
affect normal development. (A) is a composites of several images to display the whole tumor size.  
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2.2.2.2 Generating a deletion for alrm and independent RNAi lines 
 
As RNAi might cause off-target effects, we generated an alrm mutant allele to confirm the 
phenotypes we observed with the RNAi line. For this, we used PiggyBac (PBac) insertion 
lines that contain FRT sites. Expression of Flp recombinase induces recombination between 
the FRT sites of two PiggyBacs in trans, deleting the genomic region in between (Parks et al, 
2004). With this strategy, we deleted a 45 kB piece that contained the entire alrm gene region. 
Unfortunately, due to the positions of the PBac elements, we could not avoid to delete three 
other genes along with alrm (Fig. 10).  
In addition, we designed four independent RNAi constructs to complement the RNAi we used 
in the original screen (Fig. 10).  
Flies mutant for alrm and flies carrying the independent RNAi lines have not yet been tested 
in the tumor background. 
 
 
 
 
 
Figure 10: Overview of the genomic region surrounding alrm and a close up of the alrm transcript. Red bars 
indicate the target sites of the RNAi lines. Arrows mark the insertion sites of the PiggyBacs. 
 
RESULTS AND DISCUSSION – ALRM 
 
79 
2.2.2.3 A depletion of alrm does not suppress the Egr small eye phenotype 
 
Alrm has been found in a previous screen to interact with dTRAF2 and could therefore modi-
fy the activity of the JNK pathway. A common tool to test for effects on JNK signaling is the 
GMR-egr phenotype. Targeted expression of Egr in the GMR-expression domain causes apop-
tosis and an ablation of eye tissue leading to a very small adult eye. We therefore tested 
whether a knockdown of alrm would modify the GMR-egr phenotype, but did not see an in-
crease in eye size (Fig. 11, A and B). As the GMR-egr phenotype can be variable, we quanti-
fied eye size by measuring the area of the eye, but we did not find a significant difference 
with or without the alrmRNAi (Fig. 11, C). These results suggest that alrm does not play a role 
in transducing the Egr signal to induce cell death genes. 
 
 
 
 
 
 
 
 
 
 
Figure 11: A knockdown of alrm does not suppress the Egr small eye phenotype. (A) and (B) Images of 
whole eyes expressing GMR-Gal4, UAS-egr (A) or GMR-Gal4, UAS-egr and alrmRNAi (B). (C) Quantificati-
on of eye size.  
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2.2.2.4 Depletion of alrm reduces Mmp1 and Ets21C expression levels 
  
Although we did not observe an effect on the GMR-egr phenotype following alrm knock-
down, we still wanted to test if JNK pathway activity was reduced in the tumor background. 
Alrm might not influence the expression of apoptosis inducers, but the expression of other 
genes that are activated through the JNK pathway and that support tumor growth. To this end, 
we monitored the expression of Mmp1, a known target gene of the JNK pathway, by qPCR in 
control tumors and tumors that co-expressed the alrmRNAi. Upon Alrm depletion, Mmp1 levels 
were reduced about 50% suggesting that Alrm influences JNK pathway activity (Fig. 12, A). 
The expression of Ets21C, another JNK target, was also reduced, but to a lesser extent than 
Mmp1 (Fig.12, B).  
In addition to the qPCR, we performed antibody stainings for Mmp1 in tumors that were de-
pleted for Alrm and compared protein levels to control tumors. Similar to the qPCR we found 
a reduction of Mmp1 protein in tumors with an Alrm knockdown (Fig.12, C and D). However, 
as the Mmp1 distribution is patchy, it is not entirely clear if there is only less protein because 
the tumors are smaller or whether protein levels are indeed reduced. This issue needs further 
clarification, for example by quantifying the staining intensities with respect to the size of the 
tumors or by directly quantifying the amounts of protein with a western blot. 
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Figure 12: A knockdown of alrm seems to reduce the expression of JNK pathway target genes. (A) and (B) 
qPCR for Mmp1 and Ets21C of control tumors and tumors expressing alrmRNAi reveal a reduced expression of 
Mmp1 and Ets21C in tumors depleted for Alrm. (C) and (D) Confocal images of control tumors and tumors 
expressing an alrmRNAi that are stained for Mmp1. Mmp1 protein is still present in tumors depleted for Alrm. (C) 
is a composites of several images to display the whole tumor size. Scale bar: 100 μm.  
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2.2.3 Conclusions and future experiments 
 
We have shown that Alrm is important for tumor growth, as depletion decreased tumor size 
(Master Thesis, Janine Toggweiler). Moreover, we made attempts to elucidate Alrm function 
and found a potential link with the JNK pathway, as alrmRNAi decreased the expression of the 
JNK target Mmp1. However, these results need to be confirmed and supplemented with addi-
tional data to uncover the role of Alrm in tumor growth. The following sections will give an 
outlook of what experiments could be done in the future to address this. 
 
2.2.3.1 Using CRISPR/Cas9 to delete alrm 
 
While this project was in progress, a new system for gene editing termed clustered regularly 
interspaced short palindromic respeat (CRISPR)/CRISPR-associated (Cas) has been adapted 
for use in Drosophila and makes targeted mutagenesis very simple (Bassett & Liu, 2014). 
Several techniques have been used and described to deliver Cas9 and the sgRNA in flies: 1.) 
co-injection of plasmids carrying Cas9 or the sgRNA into embryos (Gratz et al, 2013), 2.) co-
injection of in vitro transcribed Cas9 mRNA and sgRNA (Bassett et al, 2013; Yu et al, 2013), 
3.) injection of sgRNA plasmids into flies that stably express Cas9 in the germline (Sebo et al, 
2014; Ren et al, 2013), and 4.) two transgenic fly strains are used: flies with germline Cas9 
expression are crossed to flies with ubiquitous expression of the sgRNA (Kondo & Ueda, 
2013). As the only limitation of targeting is the PAM sequence “NGG”, virtually any gene 
can be targeted with the CRISPR/Cas9 system.  
 
Generating a null-allele of alrm has been challenging, as the gene lies in the intron of another 
gene and the available PBac elements are located in such a way that a deletion of additional 
genes was inevitable. However, with the CRISPR/Cas9 system, it will be possible to intro-
duce specific mutations only in the alrm gene. To check if suitable sequences for designing 
sgRNAs for alrm were available, we made use of the sgRNA design tool of the Drosophila 
RNAi screening center (DRSC, http://www.flyrnai.org/crispr2/). We found four potential 
sgRNA sequences in the alrm coding sequence (CDS) that are predicted to have no off-target 
effects (Fig. 13). We cloned these sgRNAs into vectors that stably integrate into the fly ge-
nome. Once transgenic lines have been established, they can be crossed to flies expressing 
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Cas9 in their germline. With this strategy, the generation of an alrm null allele should be 
straight forward. Besides generating a mutant allele, the CRISPR/Cas9 system could also be 
used to tag endogenous Alrm with, for example, GFP to investigate its localization and to 
monitor its expression. 
 
 
2.2.3.2 More detailed analysis of alrm mutant tumors 
 
Once we have established alrm mutant flies and tested whether tumors homozygous mutant 
for alrm show growth defects, we will continue analysing alrm function. Growth of RasV12 
dlgRNAi tumors is regulated by the PI3K and the MAPK pathways that are activated down-
stream of Ras signaling as well as the JNK pathway, which is induced by loss of polarity and 
leads to the activation of the JAK/STAT pathway (Igaki et al, 2006; Willecke et al, 2011; Wu 
et al, 2010). In addition, it has been shown that Hippo pathway activity is suppressed in cells 
with polarity defects leading to increased growth (Sun & Irvine, 2011). Based on results de-
scribed in 4.2.2.4, we have evidence that a depletion of alrm might disturb JNK pathway ac-
tivity as assesseed by expression of the JNK pathway target Mmp1, but Mmp1 protein levels 
were apparently similar to those in control tumors (see Fig. 12). To clarify this issue, we want 
to analyse Mmp1 expression in alrm mutant tumor cells to be sure that alrm function is abol-
       
 
Figure 13: Schematic overview of the alrm gene region. The location of potential sgRNAs in the alrm cod-
ing sequence is indicated with red bars.  
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ished and to exclude off-target effects of the RNAi. Besides the JNK pathway, we also want 
to test the MAPK, PI3K, JAK/STAT and the Hippo pathways for changes in activity. To this 
end, we will monitor the expression of pathway target genes with qPCRs and immunostain-
ings. With these experiments, we hope to better understand how a loss of alrm affects tumor 
growth. 
 
2.2.3.3 Searching for interactors of Alrm – immunoprecipitation and mass spectrometry 
 
Alrm contains several leucin-rich repeat (LLR) sequence motifs. Typically, LLRs consist of 
20-29 amino acid residues with a conserved 11 residue motif (LxxLxLxxN/CxL). LLR se-
quences appear in proteins with distinct functions, but all of these proteins appear to be in-
volved in protein-protein interactions and many play a role in signal transduction (Kobe, 
2001). We were therefore intrigued by the idea that Alrm might serve as an adaptor protein 
for components of different signaling pathways. In order to find Alrm binding partners, we 
could precipitate Alrm protein and analyse protein complexes with mass spectrometry. A 
challenge will be to decide in which system we will perform the immunoprecipitations. The 
best system would be the RasV12 dlgRNAi tumors, however, to obtain enough material for an 
immunoprecipitation we will need to collect a vast number of tumors. Our laboratory has re-
cently established a protocol for mass isolating and sorting imaginal discs (Marty et al, 2014). 
With this protocol, about 1000 imaginal discs can be isolated in less than three hours. A key 
requirement for sorting of the imaginal discs is the expression of a fluorescent protein in the 
tissue of interest. As our tumor cells express GFP they would be good candidates for sorting. 
However, due to the genetic set-up, only half of the progeny larvae from a cross develop tu-
mors and crosses are quite laborious to prepare as a lot of virgin females are required to ob-
tain enough progeny. Because of this, it might be rather challenging to collect the required 
numbers of larvae for the mass isolation and sorting. An alternative strategy would be to per-
form the immunoprecipitation from cell lines: in this case we could either express tagged 
Alrm in wild-type cells or engineer cells as such that they are mutant for dlg and express 
RasV12 and Alrm. Using wild-type cells would be the simplest solution, yet we would first 
have to make sure that Alrm is evoking the same responses in wild-type cells as in RasV12 
dlgRNAi tumors. Once the immunoprecipitation and mass spectrometry have been performed, 
we will analyze and search the identified interactors for components of the MAPK, PI3K, 
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JNK, JAK/STAT or Hippo pathways. These pathways have previously been shown to drive 
and sustain tumor growth (Igaki et al, 2006; Wu et al, 2010; Willecke et al, 2011; Sun & 
Irvine, 2011). Potential interaction partners will then be further analyzed and validated by co-
immunoprecipitation and/or co-localization experiments and complemented with the experi-
ments described in 4.2.3.2. By combining these approaches, we might elucidate the mecha-
nisms by which loss of alrm affects tumor growth. 
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2.3 The Drosophila TNF receptor Grindelwald couples loss of cell polarity 
and neoplastic growth 
 
Wengen (Wgn, CG6531) was the only easily identifiable member of the tumor necrosis factor 
receptor (TNFR) superfamily in Drosophila, but its role in Drosophila TNF signaling has 
been controversial for a long time. Kanda et al. (2002) have retrieved Wgn from a dominant 
modifier screen for downstream components of Egr signaling and reported that a dsRNA tar-
geting wgn suppressed the Egr induced small eye phenotype. Furthermore, they found that 
full-length Wgn and Egr physically interact via their TNFR and TNF homology domain 
(Kanda et al, 2002). However, other groups were not able to confirm the interaction, but 
showed that Wengen interacts with DTRAF2 instead (Kauppila et al, 2003).  
Michael Röthlisberger, a former master student in the Basler laboratory, had generated a wgn 
knockout (KO) allele by homologous recombination. Surprisingly, a wgn knockout could not 
suppress the Egr overexpression phenotype. This is unexpected, given the results of Kanda et 
al. (2002). Since neoplastic tumors depend on Egr signaling, we have also analysed Wgn in 
this background, but found that it is not required for tumor growth (Master thesis, J. 
Toggweiler). A finding that also contrasts with the results of Kanda et al. (2002) and Kauppila 
et al. (2003). 
To solve this controversy, we were happy to assist with the investigations on Grindelwald 
(Grnd), a transmembrane protein identified in a genome-wide RNAi screen in Pierre Léopolds 
group. I reanalysed growth of RasV12 dlgRNAi tumors in a wgn knockout background and com-
pared the effects to control tumors and tumors that were depleted for Grnd. In addition, I 
stained tumors for Mmp1, a protein that is expressed in response to JNK pathway activation. 
My results clearly demonstrated that Mmp1 expression is strongly reduced in tumors in which 
Grnd is knocked-down, but not in wgn mutant tumors. 
 
These results are part of a study published in Nature: 
Ditte S. Andersen, Julien Colombani, Valentina Palmerini, Krittalak Chakrabandhu, Emilie Boone, 
Michael Roethlisberger, Janine Toggweiler, Konrad Basler, Marina Mapelli, Anne-Odile Hueber & 
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The Drosophila TNF receptor Grindelwald couples
loss of cell polarity and neoplastic growth
Ditte S. Andersen1,2,3,4*, Julien Colombani1,2,3,4*, Valentina Palmerini5, Krittalak Chakrabandhu1,2,3,6, Emilie Boone1,2,3,4,
Michael Ro¨thlisberger7, Janine Toggweiler7, Konrad Basler7, Marina Mapelli5, Anne-Odile Hueber1,2,3,6 & Pierre Le´opold1,2,3,4
Disruption of epithelial polarity is a key event in the acquisition of
neoplastic growth. JNK signalling is known to play an important
part in driving the malignant progression of many epithelial
tumours, although the link between loss of polarity and JNK sig-
nalling remains elusive. In a Drosophila genome-wide genetic
screen designed to identify molecules implicated in neoplastic
growth1, we identified grindelwald (grnd), a gene encoding a trans-
membrane protein with homology to members of the tumour nec-
rosis factor receptor (TNFR) superfamily. Here we show that Grnd
mediates the pro-apoptotic functions of Eiger (Egr), the unique
Drosophila TNF, and that overexpression of an active form of
Grnd lacking the extracellular domain is sufficient to activate
JNK signalling in vivo. Grnd also promotes the invasiveness of
RasV12/scrib2/2 tumours through Egr-dependent Matrix metallo-
protease-1 (Mmp1) expression. Grnd localizes to the subapical
membrane domain with the cell polarity determinant Crumbs
(Crb) and couples Crb-induced loss of polarity with JNK activation
and neoplastic growth through physical interaction with Veli (also
known as Lin-7). Therefore, Grnd represents the first example of a
TNFR that integrates signals from both Egr and apical polarity
determinants to induce JNK-dependent cell death or tumour
growth.
We recently carried out a genome-wide screen to identify molecules
that are required for neoplastic growth1. The condition used for this
screen was the disc-specific knockdown of avalanche (rotund
(rn).avl-RNAi; avalanche also known as syntaxin 7), a gene encoding
a syntaxin that functions in the early step of endocytosis2. rn.avl-
RNAi results in ectopic Wingless (Wg) expression, neoplastic disc
overgrowth2 (Fig. 1a, b), and a 2-day delay in larva-to-pupa transition1.
We screened a collection of 10,100 transgenic RNA interference
(RNAi) lines for their ability to rescue the pupariation delay and iden-
tified 121 candidate genes1. Interestingly, only eight candidate genes
also rescued ectopic Wg expression and neoplastic overgrowth
(Extended Data Fig. 1a). These included five lines targeting core com-
ponents of the JNK pathway (Bendless, Tab2, Tak1, Hemipterous and
Basket; Extended Data Fig. 1b). Using a puckered enhancer trap (puc-
lacZ) as a readout for JNK activity, we confirmed that JNK signalling is
highly upregulated in rn.avl-RNAi discs (Fig. 1a, b, right). One of the
remaining lines targets CG10176, a gene encoding a transmembrane
protein. Reducing expression of CG10176 by using two different
RNAi lines was as efficient as tak1 silencing to restore normal Wg
pattern and suppresses JNK signalling and neoplastic growth in the
rn.avl-RNAi background (Fig. 1c, d and Extended Data Fig. 1c–e).
Sequence analysis of GC10176 identified a cysteine-rich domain
(CRD) in the extracellular part with homology to vertebrate TNFRs
(Fig. 1e and Extended Data Fig. 2) harbouring a glycosphingolipid-
binding motif (GBM) characteristic of many TNFRs including Fas3
(Fig. 1e and Extended Data Fig. 2). We named CG10176 grindelwald
(grnd), after a village at the foot of Eiger, a Swiss mountain that lent its
name to the unique Drosophila TNF, Egr. Immunostaining and sub-
cellular fractionation of disc extracts confirmed that Grnd localizes to
the membrane (Extended Data Fig. 1f–h). Moreover, co-immunopre-
cipitation experiments showed that both Grnd full-length and Grnd-
intra, a form lacking its extracellular domain, directly associate with
Traf2, the most upstream component of the JNK pathway (Fig. 1f–h).
This interaction is disrupted by a single amino acid substitution within
a conserved Traf6-bindingmotif4 (human TRAF6 is the closest homo-
logue to Traf2; Fig. 1f–h and Extended Data Fig. 3). Overexpression of
Grnd-intra, but not full-length Grnd, is sufficient to induce JNK sig-
nalling, ectopic Wg expression and apoptosis (Fig. 1i–j and Extended
Data Fig. 4a–c), and Grnd-intra-induced apoptosis is efficiently sup-
pressed in a hep75 (JNKK)mutant background (ExtendedData Fig. 4d,
e), confirming that Grnd acts upstream of the JNK signalling cascade.
The Drosophila TNF Egr activates JNK signalling and triggers cell
death or proliferation, depending on the cellular context5. We there-
fore tested whether Grnd is required for the small-eye phenotype
generated by Egr-induced apoptosis in the retinal epithelium6,7
(GMR.egr; Fig. 2a, b). As previously shown, inhibition of JNK sig-
nalling by reducing tak1 (ref. 6) or traf2 (ref. 8) expression, or by
overexpressing puckered7, blocks Egr-induced apoptosis and rescues
the small-eye phenotype (Extended Data Fig. 5a–d). In contrast to a
previous report9, RNAi silencing of wengen (wgn), a gene encoding a
presumptive receptor for Egr, does not rescue the small-eye phenotype
(Extended Data Fig. 5e). Furthermore, the small-eye phenotype is not
modified in awgn-nullmutant background (Fig. 2c andExtendedData
Fig. 5h, m, n), confirming that Wgn is not required for Egr-induced
apoptosis in the eye. By contrast, reducing grnd levels partially rescues
the Egr-induced small-eye phenotype, producing a ‘hanging-eye’
phenotype (Fig. 2d) that is not further rescued in a wgn-knockout
(wgnKO) mutant background (Extended Data Fig. 5e–i). A similar
phenotype was previously reported as a result of non-autonomous cell
death induced by a diffusible form of Egr10 (Extended Data Fig. 5k, l).
This suggests that Grnd prevents Egr from diffusing outside of its
expression domain. Co-immunoprecipitation experiments show that
both full-length Grnd and Grnd-extra, a truncated form of Grnd lack-
ing the cytoplasmic domain, associate with Egr through its TNF-
homology domain (Fig. 2j, k). Although Grnd-extra can bind Egr, it
cannot activate JNK signalling. Therefore, we reasoned that Grnd-
extra expression might prevent both cell-autonomous and non-auto-
nomous apoptosis by trapping Egr and preventing its diffusion and
binding to endogenous Grnd. Indeed, GMR-Gal4-mediated express-
ion of grnd-extra fully rescues the Egr small-eye phenotype (Fig. 2e and
Extended Data Fig. 5j). To confirm that the removal of Grnd induces
Egr-mediated non-autonomous cell death, we generated wing disc
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clones expressing egr alone, egr 1 tak1 RNAi, or egr 1 grnd RNAi
(Fig. 2f–i). As expected, reducing tak1 levels in egr-expressing clones
prevents their elimination by apoptosis (Fig. 2f, g). Similarly, reducing
grnd levels prevents autonomous cell death, but also induces non-
autonomous apoptosis (Fig. 2h, i). This suggests that Egr, like its
mammalian counterpart TNF-a, can be processed into a diffusible
form in vivo whose interaction with Grnd limits the potential to act
at a distance. Flies carrying homozygous (grndMinos/Minos) or transhe-
terozygous (grndMinos/Df) combinations of a transposon inserted in the
grnd locus express no detectable levels of Grnd protein (ExtendedData
Fig. 6a, b) and are equally resistant to Egr-induced cell death (Extended
Data Fig. 6e–j). In addition, grndMinos/Minos mutant flies are viable and
display no obvious phenotype (Extended Data Fig. 6c, d), suggesting
that Grnd, like Egr, participates in a stress response to limit organismal
damage. Collectively, our data demonstrate that Grnd is a new
Drosophila TNF receptor that mediates most, if not all, Egr-induced
apoptosis.
TNFs probably represent a danger signal produced in response to
tissue damage to rid the organismof premalignant tissue or to facilitate
wound healing. Disc clones mutant for the polarity gene scribbled
(scrib) induce an Egr-dependent response resulting in the elimination
of scrib mutant cells by JNK-mediated apoptosis11,12. To test the
requirement for Grnd in this process, we compared scrib-RNAi and
scrib-RNAi1 grnd-RNAi clones obtained 72 h after heat shock induc-
tion. As expected, scrib-RNAi cells undergo apoptosis and detach from
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the epithelium (Fig. 3a–d). By contrast, scrib-RNAi clones with reduced
grnd expression survive (Fig. 3e, f), indicating that Grnd is required
for Egr-dependent elimination of scrib-RNAi cells. Similar results
were obtained by generating scrib2/2 mutant clones in the eye disc
(Extended Data Fig. 7a–d).
In bothmammals and flies, TNFs are double-edged swords that also
have the capacity to promote tumorigenesis in specific cellular con-
texts5. Indeed, scrib2/2 eye disc cells expressing an activated form of
Ras (RasV12) exhibit a dramatic tumour-like overgrowth and meta-
static behaviour, a process that critically relies on Egr13. RasV12/
scrib2/2 metastatic cells show a strong accumulation of Grnd and
Mmp1, and invade the ventral nerve cord11,14,15 (Fig. 3g and
Extended Data Figs 7e, 8a). Primary tumour cells reach peripheral
tissues such as the fat body and the gut, where they form micro-
metastases expressing high levels of Grnd (Extended Data Fig. 7f, g).
Reducing grnd levels in RasV12/scrib2/2 clones is sufficient to restore
normal levels of Mmp1 and abolish invasiveness in a way similar to
that observed in an egr2/2 background13 (Fig. 3h, i and Extended Data
Fig. 8a–c). Therefore, Grnd is required for the Egr-induced metastatic
behaviour of RasV12/scrib2/2 tumorous cells. Similarly, reducing grnd,
but not wgn levels, strongly suppresses Mmp1 expression in RasV12/
dlg-RNAi cells and limits tumour invasion (Extended Data Fig. 8d–g),
indicating that Wgn does not have a major role in the progression of
these tumours.
Perturbation of cell polarity is an early hallmark of tumour progres-
sion in epithelial cells. In contrast to small patches of polarity-deficient
cells, for example, scrib2/2 clones, organ compartments or animals
fully composed of polarity-deficient cells become refractory to Egr-
induced cell death and develop epithelial tumours. The formation of
these tumours requires JNK/MAPK signalling, but not Egr13,16, sug-
gesting Egr-independent coupling between loss of polarity and JNK/
MAPK-dependent tumour growth. In line with these observations,
we noticed that, in contrast to Grnd, Egr is not required to drive
neoplastic growth in rn.avl-RNAi conditions (Extended Data
Fig. 9a, b). This suggests that, in addition to its role in promoting
Egr-dependent functions, Grnd couples loss of polarity with JNK-
dependent growth independently of Egr. Disc immunostainings
revealed that Grnd co-localizes with the apical determinant Crb
in the marginal zone, apical to the adherens junction protein
E-cadherin (E-cad) and the atypical protein kinase C (aPKC; Fig. 4a
and Extended Data Fig. 9c, d). In avl-RNAi discs, Grnd and Crb
accumulate in a wider apical domain2 (Extended Data Fig. 9e, g).
Apical accumulation of Crb is proposed to be partly responsible for
the neoplastic growth induced by avl knockdown, since overexpres-
sion of Crb or a membrane-bound cytoplasmic tail of Crb (Crb-intra)
mimics the avl-RNAi phenotype2 (Extended Data Fig. 9f). We there-
fore examined whether Grnd might couple the activity of the Crb
complex with JNK-mediated neoplastic growth. Indeed, reducing grnd
levels, but notwgn, in rn.crb-intra discs suppresses neoplastic growth
as efficiently as inhibiting the activity of the JNK pathway (Fig. 4c–f
and Extended Data Fig. 9h, i). Notably, Yki activation is not rescued in
these conditions (Extended Data Fig. 9j–l), illustrating the ability of
Crb-intra to promote growth independently of Grnd by inhibiting
Hippo signalling through its FERM-binding motif (FBM)17,18.
Indeed, neoplastic growth and polarity defects induced by a form of
Crb-intra lacking its FBM (CrbDFBM-intra) are both rescued byGrnd
silencing (Fig. 4i, j). As expected, the size of rn.crbDFBM-intra;grnd-
RNAi discs is reduced compared to the size of rn.crb-intra; grnd-
RNAi discs (compare Fig. 4e, f with Fig. 4j).
Crb, Stardust (Sdt; PALS1 in humans), and Pals1-associated tight
junction protein (Patj)make up the core Crb complex19, which recruits
the adaptor protein Veli (MALS1–3 in humans)20–22. In agreement
with previous yeast two-hybrid data23, we find that Grnd binds directly
and specifically to the PDZ domain of Veli through a membrane-
proximal stretch of 28 amino acids in its intracellular domain
(Extended Data Fig. 10a–e). Grnd localization is unaffected in
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crb2/2 and veli RNAi mutant clones (Extended Data Fig. 10f–h).
However, reducing veli expression rescues the patterning defects and
disc morphology of rn.crb-intramutant cells (Fig. 4g, h), suggesting
that Grnd couples Crb activity with JNK signalling through its inter-
action with Veli. Interestingly, aPKC-dependent activation of JNK
signalling16 also depends on Grnd (Fig. 4k, l). aPKC is capable of
directly binding and phosphorylating Crb, which is important for
Crb function24. This suggests that aPKC, either directly or through
Crb phosphorylation, activates Grnd-dependent JNK signalling in res-
ponse to perturbation of apico-basal polarity.
Our data are consistent with a model whereby Grnd integrates
signals from Egr, the unique fly TNF, and apical polarity determi-
nants to induce JNK-dependent neoplastic growth or apoptosis in a
context-dependent manner (Fig. 4m). Recent work reveals a correla-
tion between mammalian Crb3 expression and tumorigenic potential
in mouse kidney epithelial cells25. The conserved nature of the Grnd
receptor suggests that specific TNFRs might carry out similar func-
tions in vertebrates, in which the link between apical cell polarity and
tumour progression remains elusive.
Online ContentMethods, along with any additional Extended Data display items
andSourceData, are available in theonline versionof thepaper; referencesunique
to these sections appear only in the online paper.
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3 Concluding remarks on Drosophila tumor models 
 
Defects in signal transduction and cell-cell communication induced by loss of function of 
tumor suppressor genes or gain of function of oncogenes are key in transforming a healthy 
cell into a malignant derivative. Studies in Drosophila have been seminal in understanding the 
function of many oncogenes and tumor suppressor genes and in dissecting the complex regu-
lations of signaling pathways; and the fly continues to reveal important concepts, as shown in 
this thesis and as discussed in sections 1.1.2. Despite the tremendous contributions to our un-
derstanding of basic cancer biology, Drosophila has only marginally been involved in finding 
clinically relevant cancer therapeutics. The Cagan laboratory has been one of the few groups 
that has tested therapeutic compounds in a Drosophila model of thyroid cancer and an identi-
fied kinase inhibitor has been subsequently advanced into clinical trials for treatment of thy-
roid cancer (Vidal, 2005). A factor limiting the utility of Drosophila for cancer research is 
clearly the complexity of many tumors that might go beyond what can be modelled in Dro-
sophila and a lack of comparable organs. The underlying biology of each tissue affects the 
efficacy of a specific drug, as its application can lead to completely different outcomes in 
cancers originated from different tissues even if the genetic lesions are similar. Nevertheless, 
the Cagan lab has proven that Drosophila can be useful in identifying new drugs, but the can-
cer optimally presents a simple genetic profile such as dependency on one single oncogene. 
Finding an efficient screening system might be a second obstacle in identifying small mole-
cule compounds in Drosophila: ideally a phenotype should be amenable for quick analysis to 
facilitate evaluation of compounds. Such a system has been set up by the Brumby and Rich-
ardson groups to screen compounds in RasV12 scrib-/- tumors and could be adapted for use in 
other tumor models as well (Willoughby et al, 2012). With such a platform at hand the role of 
Drosophila tumor models might be advanced from only contributing the understanding of 
basic cancer biology to also identifying relevant therapeutic compounds.  
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4 Appendix 
 
4.1 Loss of function and gain of function phenotypes of other Drosophila 
ETS genes in a wild-type background  
 
As discussed in the introductory section 1.2.2, only a few of the Drosophila ETS proteins 
have been linked to growth and development of eye or wings. To assess the role for other 
Drosophila ETS proteins in these tissues, we knocked down and ectopically expressed them 
in the developing eye and wing by means of eye disc and wing disc specific Gal4 drivers 
(eye: GMR-Gal4 (posterior to the morphogenetic furrow), eyFlp-act>>Gal4 (entire eye disc); 
wing: nubbin (nub)-Gal4 (wing pouch) and hedgehog (hh)-Gal4 (posterior compartment). 
Table 2 summarizes the phenotypes observed and detailed descriptions for each gene are 
found in sections 4.1.1. – 4.1.8. Although a function for Ets21C is described already in earlier 
sections of this thesis and Pnt and Aop have been studied in detail by other groups, they were 
also included in the analysis for comparisons. 
 
 Table 2: Overview of phenotypes caused by a depletion or overexpression of Drosophila ETS genes in the 
developing wing and eye tissue. 
 
 
 
 
 
Phenotypes 
 
Knockdown Overexpression 
 
Eyes Wings Eyes Wings 
pnt much smaller, rough normal lethal normal 
aop much smaller or lethal normal smaller and rough smaller, abnormal veins 
Ets21C slightly larger  missing parts of veins much smaller smaller, blisters 
Ets98B smaller smaller, vein defects rough eye or lethal lethal 
Ets96B normal slightly smaller normal normal 
Ets65A normal normal normal normal 
Ets97D slightly larger normal slightly smaller, rounder  smaller 
E74 normal smaller ,extra veins n.d. n.d. 
APPENDIX – ETS GENES 
 
89 
4.1.1 Pointed 
 
From previous studies, Pointed (Pnt) is known to play an important role as transcription factor 
of the MAP kinase pathway (Brunner et al, 1994). In agreement with its described function, a 
knockdown of pnt in the developing eye lead to severe reductions in size and defects in mor-
phology (Fig. 14, A, D, E and H). Ectopic expression in the eye even resulted in pupal lethali-
ty (Fig. 14, A-C and E-G). Interestingly, a knockdown in wing imaginal discs does not cause 
any defects, suggesting that Pnt function is dispensable for wing development (Fig. 14, I-L). 
Effects of overexpressing Pnt in the wing still need to be determined.  
 
 
 
Figure 14: Eye and wing phenotypes resulting from depleting or ectopically expressing Pnt in imaginal tissue. 
Images of adult eyes (A-H) and wings (I-L) are shown. 
 
4.1.2 Anterior open  
 
In contrast to Pnt, Anterior open (Aop) represses the transcription of MAPK targets and is 
inactivated if the pathway is active (Brunner et al, 1994; O’Neill et al, 1994). We would 
therefore expect similar defects from a missexpression or downregulation as observed for pnt. 
Depletion in eye discs also resulted in a rough eye phenotype and overexpression is lethal 
(Fig. 15, A-H). Defects observed in wing discs are only mild, Aop overexpression leads to 
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wing vein defects (Fig. 15, I-N). A depletion of Aop does not affect wing patterning, but 
might reduce size slightly (Fig. 15, I, K-M, O and P). 
 
 
 
Figure 15: Eye and wing phenotypes resulting from depleting or ectopically expressing Aop in imaginal tissue. 
Images of adult eyes (A-H) and wings (I-P) are shown. 
 
4.1.3 Ets21C 
 
Ets21C has been poorly characterized so far. It has only been found up-regulated in response 
to bacterial infection or tissue damage. We recently found that Ets21C seems to positively 
regulate growth of neoplastic tumors in Drosophila (this thesis). Interestingly, in a wild-type 
background opposite phenotypes were observed. Overexpression of Ets21C causes very small 
eyes or pupal lethality and also small wings that do not properly unfold and show defective 
veins and blisters (Fig. 16, A, B, E, F, I, J, M and N). A knockdown of Ets21C in eye tissue 
leads to slightly larger (Line 51225) or normal (Line 106153) eyes (Fig. 16, A, C-E, G and 
H). Depletion of the gene product in wings leads to different phenotypes. With line 51225 
wings seem to be slightly larger as well and miss parts of longitudinal veins L2 or L4 as well 
as L5 ( Fig. 16, I, K, M and O). Line 106153, however, seems to cause smaller or normally 
sized wings without patterning defects (Fig. 16, I, L, M and P).  
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Figure 16: Effects of Ets21C depletion or ectopic expression in eye and wing tissue. Images of adult eyes (A-H) 
and wings (I-P) are shown. 
 
4.1.4 E74 
 
E74 mutants have difficulties to complete metamorphosis and usually die as pupae (Fletcher 
et al., 1995). A depletion of E74 in the developing eye does not affect eye size and 
morphology (Fig. 17, A-D). In contrast, a knockdown of E74 in the wing imaginal disc 
resulted in reduced wing size and extra veins (Fig. 17, E-H).  
 
 
Figure 17: Effects of E74 depletion in eye and wing tissue. Images of adult eyes (A-D) and wings (E-H) are 
shown. 
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4.1.5 Ets98B  
 
Overexpression of Ets98B with GMR-Gal4 led to abnormal development of the ommatidia 
resulting in a rough eye phenotype (Fig. 18, E and F). Ectopic expression in the entire eye 
disc even led to pupal lethality (Fig. 18, G and H). A knockdown of Ets98B in eye tissue 
resulted in very different phenotypes depending on the driver and the RNAi line. In 
combination with eyFlp, line 10932 resulted in smaller eyes that were only composed of cells 
that did not express the RNAi as they were colored white or light orange (Fig., 18, compare A 
and C). The cells that expressed the RNAi would be of dark red color, suggesting that these 
cells have died (Fig. 18, C). This phenotype was not observed with the second RNAi line 
(107292) (Fig. 18, D) Also, a knockdown of Ets98B with GMR-Gal4 did not affect eye 
development, except for line 107292 that seemed to enlarge eye size slightly (Fig. 18, G and 
H). In wing imaginal discs, ectopic expression of Ets98B led to pupal lethality (Fig. 18, J and 
N). Downregulation of Ets98B in the wing pouch or the posterior compartment resulted in 
smaller and not correctly unfolded wings with patterning defects such as thicker or missing 
veins (Fig. 18, I, K, L-M, O and P). 
 
 
 
Figure 18: Effects of Ets98B depletion or ectopic expression in eye and wing tissue. Images of adult eyes (A-H) 
and wings (I-P) are shown. 
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4.1.6 Ets96B  
 
Ets96B has not been functionally characterized so far. Overexpression in the whole eye disc 
caused slightly enlarged eyes (Fig. 19, A and B). Wings did not seem to be affected (Fig. 19, 
G, H, J and K). A a knockdown of Ets96B led to a slight reduction in eye and wing size (Fig. 
19, A, C and F, G, I-J and L). This could, however, also been due to normal size variablity 
within the population.  
 
 
 
Figure 19: Effects of Ets96B depletion or ectopic expression in eye and wing tissue. Images of adult eyes (A-F) 
and wings (G-L) are shown. 
 
4.1.7 Ets65A 
 
Ets65A has been identified by Chen et al., 1992, but its function remained unknown. Wing 
and eye size as well as morphology were normal upon overexpression and knockdown (Fig. 
20, A-B, D-H, I and L). Only a depletion in the whole eye or ectopic expression in the 
posterior compartment resulted in smaller eyes or wings (Fig. 20, C and K). 
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Figure 20: Effects of Ets65A depletion or ectopic expression in eye and wing tissue. Images of adult eyes (A-F) 
and wings (G-L) are shown. 
 
4.1.8 Ets97D  
 
Ets97D is required for the proper formation of the oocyte (Gajewski & Schulz, 1995; Schulz 
et al, 1993). Its function in the development of the adult eyes and wings, however, has not 
been studied yet. Overexpression of Ets97D neither affected eye or wing size nor morphology 
(Fig. 21, A, B, E, F, I, J, M and N). A knockdown of Ets97D with GMR-Gal4 also had no 
apparent effect (Fig. 21, G and H). Depletion of the gene product in the whole eye, however, 
reduced eye size and lead to a more roundish shape (Fig. 21, C and D). A similar effect was 
observed in wings (Fig. 21, I, K-M, O and P). Particularly the knockdown in the wing pouch 
with line 108936 led to a dramatic reduction in size and defects in wing unfolding (Fig. 21, 
L). This phenotype is very similar to the one observed with an RNAi line targeting Ets98B 
(compare Fig. 18, L and P to Fig. 21, L and P).  
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Figure 21: Effects of Ets97D depletion or ectopic expression in eye and wing tissue. Images of adult eyes (A-H) 
and wings (I-P) are shown. Note the extensive wing size reduction upon knockdown with line 108936 (L). 
 
4.1.9 Conclusions 
 
Based on the roles of Pnt and Aop during eye development and the interesting phenotype of 
Ets21C overexpression in eyes (see Ets21C Manuscript Sup. Fig. 2), we tested other members 
of the Drosophila ETS gene family for a role in eye and wing development. Two members, 
Ets96b and Ets65A do not seem to affect eye or wing development as neither depletion nor 
overexpression of the gene product caused an apparent phenotype. However, a depletion of 
Ets98B, Ets97D and E74 resulted in defective wings, suggesting an involvement of these 
genes in wing growth and patterning. A depletion of Ets98B also caused a rough eye pheno-
type and smaller eyes, but these phenotypes varied a lot depending on the driver and RNAi 
line used. The similarity between the Ets97D and Ets98B knockdown phenotype in wings is 
striking and demands further investigations to test if the two proteins act in a common path-
way or whether the identical phenotypes were caused by RNAi off-target effects. The pheno-
types of Ets98B and Ets97D were only similar with RNAi, but not if the proteins were over-
expressed in wing or eye tissue. Ets97D did not cause any effect, but Ets98B overexpression 
exerted a strong effect on wing or eye tissue as it caused lethality or a rough eye phenotype. 
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Here, it would be interesting to perform further experiments to understand how Ets98B over-
expression affects eye and wing development.  
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4.2 Methods 
 
Fly husbandry 
 
Flies were grown under standard conditions at 25°C. Fly stocks used in sections 2.1.1 – 2.1.5, 
2.2 and Appendix 4.1 are listed in a separate appendix (4.3). 
 
Generation of the alrm deletion 
 
Alrm was removed with an in trans recombination of flanking PiggyBac (PBac) elements 
according to the strategy of Parks et al. (Parks et al, 2004) (see Fig. 10). PBac elements XP (-) 
Fur1d04883 and WH (+) Fur1f00663 were combined with hsp70-flp on the X-chromosome and 
then brought together in trans. yw, hsFlp; XP Fur1d04883/WH Fur1f00663 progeny were heat-
shocked two days AEL for 1h at 37°C. The heat-shock was repeated the next two days. Single 
adult males were crossed to balancer chromosomes and progeny were screened for positive 
recombination. Both PBac elements initially carry a mini-white gene, restoring red eye color 
in flies mutant for the white (w) gene. Successful recombination between XP elements in mi-
nus direction and WH elements in plus direction, removes the mini-white sequences of both 
PBac elements, resulting in flies with white eyes. We therefore could easily screen flies for 
white eye color. Isogenic stocks were established from three independent white eyed males 
and successful recombination was confirmed by PCR with primers XP 5` plus and WH 5` 
minus according to Parks et al. (Parks et al, 2004). A product is only yielded if recombination 
was successful as the region between the primer binding sites is otherwise too long.  
 
Cloning and generation of transgenes  
 
Ets21C phosphomutant 
A plasmid with the open-reading frame of the Ets21C A isoform was obtained from FlyORF 
and the modification of the phosphorylation site was introduced with a simple PCR. As the 
putative phosphorylation sites lies very close to the C-terminus, we designed a 37 nt long 
primer 5`- TCTAGACTAGTTGAATGCATTTGTGGTGGGTGCGACC – 3` that contained a 
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substitution of the threonine codon of amino acid 468 with alanine, the remaining sequence 
including stop codon and an XbaI cut site. In addition to the XbaI site, we introduced an 
Acc65I site a the start of the coding sequence for subcloning into pUAST.attB.  
 
Ets21CΔSOCS 
To delete the SOCS domain, we performed an overlapping PCR that removed amino acids 
57-110 of Ets21C. The truncated protein version was cloned into pUAST.attB via 5` Acc65I 
and 3` XbaI cut sites that had been attached in the PCR. 
 
Alrm overexpression 
To generate the alrm overexpression construct, we amplified the alrm sequence from genomic 
DNA and attached 5` Acc65I and 3` XbaI cut sites for subcloning into pUAST.attB. 
 
Independent alrm RNAi lines 
Dharmacon algorithm was used to design the RNAi target site of 21-mer oligos. We choose 
four different target sites in the alrm coding sequence that were not overlapping with the se-
quence of the VDRC RNAi line 14738 for further processing. Target sites were converted 
into 71 nt long oligos using http://flybuzz.berkeley.edu/cgi-bin/constructHairpin.cgi and a 5` 
NheI and 3` EcoRI site was attached. After an annealing step, oligos were inserted into 
pNE3.2 via NheI and EcoRI sites. pNE3 vector was obtained from B. Haley and is a deriva-
tive of pUAST-attB (Haley et al, 2008; Bischof et al, 2007). 
Sequences of the oligos used: 
 
HP5: 5`- ctagcagtattgggaaacgttcagggttatagttatattcaagcatattacccgaaggtttcccaatgcg - 3` 
HP6: 5`- ctagcagtaaatttctcttggagttttaatagttatattcaagcatataaaaactcctagagaaatttgcg - 3 
HP7: 5`- ctagcagtcgtgattggtggcagtgataatagttatattcaagcatataatcactgcgaccaatcacggcg - 3 
HP8: 5`- ctagcagttcgcatgttgcaggagatgtatagttatattcaagcatattcatctcctccaacatgcgagcg -3 
 
All constructs were inserted via the ΦC31 integrase system into landing site ZH-86Fb.  
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Deletion of AP-1 sites 
Putative AP-1 sites in the Ets21C genomic region (see Fig. 8) were deleted with overlapping 
PCRs according. An Ets21C Bacterial artificial chromosome (Bac) (CH322-41A08) served as 
template for the PCR. With this strategy we have generated two mutant fragments, the first 
contained three deleted AP-1 sites and the second the remainig AP-1 site. The fragments with 
the deleted sites were then exchanged in two steps with the wild-type sequence via ClaI and 
XbaI and XbaI and Pfl23II sites. The entire Ets21C genomic region including upstream and 
downstream sequences up to the next neighboring genes has previously been amplified from 
the Ets21C Bac and has been subcloned into pGEMeasy-T vector (Promega). Once the wild-
type sequence had been exchanged for the mutant one, the entire fragment was swapped into a 
pattB vector via 5` NotI and 3` Acc65I sites that had been attached in the initial PCR to am-
plify the Ets21C gene region. The same was done with the wild-type fragment. 
 
Immunofluorescence 
 
Fixation and immunostainings of Drosophila eye imaginal discs and tumors were performed 
according to standard protocols. Primary antibody used in this study was: anti-Mmp1 (1/200, 
3B8D12, Developmental studies hybridoma bank (DSHB)). Alexa fluor 594 (1/500, Molecu-
lar Probes) was used as label for the secondary antibody. Imaginal discs were mounted in 
VectaShield (Vector Laboratories). Images were taken with a Zeiss Lsm710 confocal micro-
scope and processed with ImageJ and Adobe Photoshop.  
 
Quantification of adult eye size 
 
Images of adult eyes were taken with an Axioplan camera. Eye area was mesured in ImageJ 
by manually outlining borders of the eye and using the „measure and label“ function of the 
„Analyze“ plugin of ImageJ to count the number of pixels included in the outlined area 
(Abràmofff et al, 2005). 
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RNA isolation and real-time PCR 
 
For RNA isolations, larvae were dissected in Ringers plus 0.05% Tween-20 and tumors were 
collected in an 1.5 ml Eppendorf tube. Tumors were centrifuged for 10 min at 4°C and pellets 
were snap freezed in liquid nitrogen, stored at -80°C or processed further. For each experi-
ment total RNA was isolated from 30 tumors or 45 wild-type eye discs with the indicated 
genotypes using the NucleoSpin RNA kit (Machery Nagel). Following an additional Dnase 
digest for 1h at 37°C (DNA-freeTM kit, Ambion), 500 ng of total RNA was used for cDNA 
synthesis with the transcriptor High Fidelity cDNA Synthesis Kit (Roche) using oligo-dT 
primers. Quantitative PCR reactions were performed in triplicates using the MESA Green 
qPCR Mastermix Plus for SYBR Assay (Eurogentec) and an ABI Prism SDS 7900 HT (Ap-
plied Biosystems). All measurements of transcript levels were normalized to actin-5C, alpha-
tubulin and TATA box binding protein (TBP). Primers were designed with Roche Universal 
Probe Library or with Primer3plus. When ever possible an intron-spanning assay was chosen. 
Primers used were: Ets21C: F: caacgacgacgaaccaaat, R: gttcgcgttggacgaatc, Mmp1: F: 
gaaggctcggacaacgagt, R: gtcgttggactggtgatcg, actin: F: gcccatctacgagggttatgc, R: aatcgcgac-
cagccagatc, alpha-tubulin at 84C: F: gccagatgccgtctgacaa, R: agtctcgctgaagaaggtgttga, TATA 
binding protein: F: cgcgcatcatccaaaagc, R: gccgaccatgttttgaatcttaa 
Quantitative PCR reactions based on DNA isolated from ChIP experiments described below 
were performed according to the same protocol as RNA based reactions, but only in dupli-
cates. Reactions were run on input chromatin and ChIP specific DNA. Reactions with no 
DNA served as negative control. Differences in cycle thresholds (cts) were normalized to a 
control primer pair and fold enrichment was calculated based on the ΔΔct method. Primers 
used were:  
 
Mmp1_5: F: gaacagagcgaatggaaagg, R: ctgttggaaagtgggattgg,  
Mmp1_6: F: tcgctgacgataaggtggat, R: ctcttcgcagaaatcccaac,  
Mmp1_7: F: atgaatctgcggtctggatt, R: ttcggtgaaacatacactttcc 
Mmp1_8: F: ggcaccaccccattaatatc, R: attgctcaggccgattactg 
Mmp1_10: F: tcggaatcccctgagtaatg, R: attcatttgccttgcacgtt 
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Chromatin immunoprecipitation (ChIP) 
 
ChIP was done on 150 RasV12 dlgRNAi tumors expressing HA-tagged Ets21C. Tumors were 
dissected in pools of 50 tumors and fixed in 1% formaldehyde and PBS-Tween 20 (0.1%) for 
10 min at room temperature. Crosslinking was stopped with 125 mM glycine for 5 min at 
room temperature and tumors were washed twice with PBS-Tween 20 (0.1%) plus protease 
inhibitors (Mini EDTA free, Roche). After a centrifugation step at 5000 g, the supernatant 
was removed and 250 μl lysis buffer was added (5mMPIPES at pH8.0, 85mMKCl, 0.5% NP-
40, protease inhibitors). The sample was snap frozen in liquid nitrogen and stored at -80°C 
until further processing.  
The ChIP was performed as described in (Schertel et al, 2015) with the following modifica-
tions: For sonication the following parameters were used (duty cycle 10%, intensity, 5; cy-
cle/burst, 200; time, 45s) to obtain fragments of an average size of 500 bp. Three sonication 
reactions were pooled to obtain material from 150 tumors for the IP. 2% of the chromatin was 
kept as input at 4°C until reverse crosslinking and elution steps. The two final wash steps after 
incubation of antibody-chromatin complexes with beads were done with additional 0.25% 
SDS. Finally, DNA was eluted in 20 μl H2O and stored at -20°C until further use. The anti-
body used was Rabbit anti-HA Chip grade (ab9110, Abcam). 
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4.3 Fly stocks 
 
The following section lists fly stocks that have been used or generated during this thesis. 
Stocks used in section 4.2 and section 4.3 are listed separately in the manuscripts. 
 
General fly stocks 
 
yw; Sp/CyO; MKRS/TM6b 
yw; Sp/SM5; MKRS/TM6b 
yw; Sp/CyO; TM2/TM6b      BK9 
 
Sections 4.1.1 – 4.1.5 l additional experiments on Ets21C 
 
eyFlp; act>y+>Gal4, UAS-GFP/CyO, tub-Gal80;UAS-RasV12/TM6b  
eyFlp; Sp/CyO; act>CD2>Gal4, UAS-GFP/TM6b  
eyFlp; UAS-RasV12, UAS-dlgRNAi/CyO, tub-Gal80; act>CD2>Gal4, UAS-GFP/TM6b 
yw; UAS-dlgRNAi , UAS-Ets21CRNAi 51225/CyO; MKRS/TM6b 
yw; UAS-dlgRNAi/CyO; UAS-Ets21CHA/TM6b 
Ets21C RNAi: VDRC 51225 (II) 
dlg RNAi: VDRC 41134 (II) 
yw; Sp/CyO; UAS-Ets21CHA (86Fb)/TM6b    FlyORF 
yw; Sp/CyO; UAS-Ets21CT468A (86Fb)/TM6b 
yw; Sp/CyO; UAS-Ets21CΔSOCS (86Fb)/TM6b 
yw; Sp/CyO; UAS-Ets21Cwt (86Fb)/TM6b 
 
Section 4.2 evaluation of alrm 
 
eyFlp; Sp/CyO; act>CD2>Gal4, UAS-GFP/TM6b  
eyFlp; UAS-RasV12, UAS-dlgRNAi/CyO, tub-Gal80; act>CD2>Gal4, UAS-GFP/TM6b 
alrm RNAi: VDRC 14738 (II) 
y w; Sp/CyO; UAS-alrm/TM6b 
APPENDIX – FLY STOCKS 
 
103 
w; GMR-Gal4; +/+ 
y wFlp; Sp/CyO; UAS-Egr86Fb/TM6b 
y w; Sp/CyO; alrmRNAi (HP5)/TM6b 
y w; Sp/CyO; alrmRNAi (HP6)/TM6b 
y w; Sp/CyO; alrmRNAi (HP7)/TM6b 
y w; Sp/CyO; alrmRNAi (HP8)/TM6b 
y w; Sp/CyO; alrmΔd04883-f00663/TM6b 
 
Appendix 7.2 Loss and gain of function of other Drosophila ETS genes during develop-
ment 
 
ey Flp; Sp/CyO; act>CD2>Gal4, UAS-GFP/TM6b  
y w Flp; nub-Gal4; +/+ 
y wFlp; Sp/CyO; hh-Gal4/TM6b 
w; GMR-Gal4; +/+ 
pointed RNAi: VDRC 105390 (II) 
ywFlp; ; UAS-PntRB(86Fb)/TM3     FlyORF 
ywFlp; ; UAS-PntRD(86Fb)/TM3     FlyORF 
aop RNAi: BL 35404  
aop RNAi: BL 34909 
y w; Sp/CyO; UAS-aop(86Fb)/TM6b     FlyORF 
E74 RNAi: VDRC 105301 (II) 
Ets21C RNAi: VDRC 51225 (II) 
Ets21C RNAi: VDRC 106153 (II) 
 y w; Sp/CyO; UAS-Ets21CHA (86Fb)/TM6b 
Ets98B RNAi: VDRC 10932 (II) 
Ets98B RNAi: VDRC 107292 (II) 
yw; Sp/CyO; UAS-98B86Fb 
Ets96B RNAi: VDRC 30552 (I) 
y w; ; UAS-96B86Fb/TM3      FlyORF 
Ets65A RNAi: VDRC 15355 (I) 
yw; Sp/CyO; UAS-65A(86Fb)/TM6b     FlyORF 
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Ets97D RNAi: VDRC 12633 (III) 
Ets97D RNAi: VDRC 108936 (II) 
y w; ; UAS-97D86Fb/TM3      FlyORF 
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4.4 Plasmid list 
 
This table lists plasmids that have been used or generated in this thesis. 
 
Name Construct Cloning details 
pJT01 pUASTattB – Ets21CT468A Ets21C ORF into pUAST via Acc65I, XbaI, site 
directed muta T468A 
pJT02 pUASTattB – Ets21CΔEts Ets21C ORF into pUAST via Acc65I, XbaI, dele-
tion of aa 254-339. 
pJT03 pUASTattB – Ets21CΔPnt Ets21C ORF into pUAST via Acc65I, XbaI, dele-
tion of aa 143-214. 
pJT04 pUASTattB – Ets21CΔSOCS Ets21C ORF into pUAST via Acc65I, XbaI, dele-
tion of aa 57-110. 
pJT05 pUASTattB – Ets21Cwt 
 
Ets21C ORF into pUAST without HA-tag 
pJT06 pGEM-easyT – genomic 
Ets21CWT 
PCR of Ets21C genomic region (10kB) from 
BAC into pGEM-easyT 
pJT07 pGEM-easyT – genomic 
Ets21CΔAP-1 (1-3) 
PCR of Ets21C genomic region (ca. 4kB) from 
BAC to delete AP-1 sites 1-3 into pGEM-easyT 
pJT08 pGEM-easyT – genomic 
Ets21CΔAP-1 (4)  
PCR of Ets21C genomic region (ca. 2kB) from 
BAC to delete AP-1 site 4 into pGEM-easyT 
pJT09 pGEM-easyT – genomic 
Ets21wt_ΔAP-1 (1-3) 
pJT07 swapped into pJT06 via ClaI and XbaI 
pJT10 pGEM-easyT – genomic 
Ets21C ΔAP-1all 
pJT08 swapped into pJT10 via XbaI and Pfl23II 
sites  
pJT11 pattB genomic Ets21Cwt Genomic Ets21Cwt swapped into pattB via NotI 
and Acc65I 
pJT12 pattB genomic Ets21CΔAP-1all Genomic Ets21CΔAP-1(1-4) in pJT10 swapped into 
pattB via NotI and Acc65I 
pJT13 pUAST-alrm PCR of alrm CDS cloned into pUAST via Acc65I 
and XbaI 
pJT14 pNE3.2_Ets21CHP1 Ets21C oligo HP1 cloned into pNE3.2 via NheI 
and EcoRI 
pJT15 pNE3.2_Ets21CHP2 Ets21C oligo HP2 cloned into pNE3.2 via NheI 
and EcoRI 
pJT16 pNE3.2_Ets21CHP3 Ets21C oligo HP3 cloned into pNE3.2 via NheI 
and EcoRI 
pJT17 pNE3.2_Ets21CHP4 Ets21C oligo HP4 cloned into pNE3.2 via NheI 
and EcoRI 
pJT18 pNE3.2_alrmHP5 Alrm oligo HP5 cloned into pNE3.2 via NheI and 
EcoRI 
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pJT19 pNE3.2_alrmHP6 Alrm oligo HP6 cloned into pNE3.2 via NheI and 
EcoRI 
pJT20 pNE3.2_alrmHP7 Alrm oligo HP7 cloned into pNE3.2 via NheI and 
EcoRI 
pJT21 pNE3.2_alrmHP8 Alrm oligo HP8 cloned into pNE3.2 via NheI and 
EcoRI 
pJT22 pUAST – HA Ets21CWT 5` NheI site added to Ets21CWT and swapped 
into pRN155. 
pJT23 pUAST– HA Ets21CΔEts 5` NheI site added to Ets21CΔEts and swapped 
into pRN155. 
pJT24 pUAST– HA Ets21CΔPnt 5` NheI site added to Ets21CΔPnt and swapped 
into pRN155. 
pJT25 pUAST – HA Ets21CΔSOCS 5` NheI site added to Ets21CΔSOCS and 
swapped into pRN155. 
pRN159 pUAST – HAFos  Fos CDS between NheI and XbaI sites, generated 
by R. Narasimamurthy 
pRN151 pUAST – JunFLAG  
 
generated by R. Narasimamurthy 
pRN36 pUAST – dTak1  
 
generated by R. Narasimamurthy 
 tub-Gal4 
 
obtained from A. Franz 
 pUAST – GFP  
 
obtained from D. Zimmerli 
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4.5 Primer list 
 
The following primers have been used for genotyping, cloning or sequencing. 
 
    Nr.  Name Sequence 5`- 3` 
 
Restriction 
sites 
JT001 Ets21CAcc65I gggtaccatggccattctacagaatagc Acc65I 
JT002 Ets21CXbaI2 cgaatctagatcagttgaatgcatttgtgg XbaI 
JT003 CG11910mRNA taccatggcggtactctggt   
JT004 CG11910mRNA rev ccggctatagcttcatcttcat   
JT005 CG11910Acc65I cgggtaccatggcggtactctggtgg Acc65I 
JT006 CG11910XbaI cgtctagactatagcttcatcttcatctcc XbaI 
JT007 Ets21CmRNA gcttaatggccattctacagaatag   
JT008 Ets21CmRNA tcagttgaatgcatttgtggtg   
JT009 hsp70 ctgccaagaagtaattattgaatac   
JT010 SV40 ctgtaggtagtttgtccaattatgtc   
JT011 CG11910_seq atcgattgccagccaaatttagg   
JT012 CG11910_seq2 ggaaatcagttgaagcagctg   
JT013 CG11910_seq2 gtttcttgaacaatccctctgg   
JT014 CG11910_seq3 ccaatgtgagcagtctggattt   
JT015 Ets21C mRNA gcaggaacatcccagcttaatg   
JT016 Ras85D_Exon1 cacgtttcacgtcactttcg   
JT017 Ras85D_Exon2 (CDS) ctcgattgtggggtcgtact   
JT018 VDRC41134_IR cgcgaattccacacaccacccgacccaag   
JT019 VDRC41134_IR cgctctagaccattttaatcgcccgctcgt   
JT020 VDRC51225_IR cgcgaattcgctcaggcgcagggaggaga   
JT021 VDRC51225_IR cgctctagacctggtcgtagtttcccgcagaag   
JT022 VDRC_hsp70 gaggcgcttcgtctacggagcgac   
JT023 Ets21C_B  atgagcgtcagcgtggac   
JT024 Ets21C_B tcagttgaatgcatttgtggtgg   
JT025 VDRC41134_IR cgcgaattccacacaccacccgacccaag   
JT026 VDRC41134_IR cttgggtcgggtggtgtgtggaattcgcg   
JT027 41134_IR aagcgagagtacgaggtgga   
JT028 Hsp70_rev gtattcaataattacttcttggcag   
JT029 Ets21CGen_NotI gcggccgcaatgtttcaaccagcag NotI 
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JT030 Ets21CGen_NotI2 gcggccgctacaatggaatg NotI 
JT031 pLacZ fwd cagctggcgtaatagcgaaga   
JT032 pLacZ rev cttcctgtagccagctttcatc   
JT033 Ets21CGen_XbaI cgtcgaggttctagatctgtacc XbaI 
JT034 Ets21C_Ex1 fwd gtactactacgacaagaacatcatgac   
JT035 Ets21C_3`UTR gagacctcgtatggaataaaggac   
JT036 Ets21C_Ex1End_2 tcctcctccgcctccactt   
JT037 Ets21C_Ex2 atccgtaccagctgctga   
JT038 Ets21C_Ex1 rev cggcgtggtgattgtaggaa   
JT039 sEts21C_Ex4 fwd ccaagtggaaagctcatgg   
JT040 sEts21C_Ex4_fwd2 acagggccaaagtgaagtga   
JT041 sEts21C_Ex4_fwd3 gcagcagtagctccacca   
JT042 sEts21C_Ex3 fwd aacaatccaatcgggtcaaa   
JT043 sEts21C_Ex2 fwd tctcctctcgctcgctct   
JT044 sEts21C_Ex1End rev atcaggtgctccgtgtagg   
JT045 T7 fwd taatacgactcactataggg   
JT046 SP6 rev tatttaggtgacactatag   
JT047 attB rev atg atg gac cag atg ggt gag g   
JT048 Mut. Ets21C fwd ggtcgcacccaccacaaatg   
JT049 Mut. Ets21C rev catttgtggtgggtgcgacc   
JT050 Ets21C_Ex4 rev agactaagccataagaggacatagg   
JT051 Ets21C_Ex3 rev ggctaaaagacacagttccca   
JT052 Ets21C_Ex4_cds fwd cgacaggtttcccaaggat   
JT053 pLacZ rev tcttcgctattacgccagctg   
JT054 attB fwd cctcacccatctggtccatcat   
JT055 Bac 41A08 fwd gggcaggcacataaatctgg   
JT056 Bac 41A08 rev agagctcccttgatgtcacc   
JT057 Ets21C_SOCS_rev gtgtcgccagcgggagcgtctccttcgcttccag   
JT058 Ets21C_SOCS_fwd ctggaagcgaaggagacgctcccgctggcgacac   
JT059 Ets21C_Pnt_fwd gccatctcctcgaaggaactagcttataccacgccaccg   
JT060 Ets21C_Pnt_rev cggtggcgtggtataagctagttccttcgaggagatggc   
JT061 Ets21C_Ets_fwd caaggctcagggggccaaaatggccgcatgccaggctc   
JT062 Ets21C_Ets_rev gagcctggcatgcggccattttggccccctgagccttg   
JT063 Ets21C_Ets_fwd2 gacttccacggtctgatgggacttccacggtctgatgg   
JT064 Ets21C_Ets_rev2 ccatcagaccgtggaagtcccatcagaccgtggaagtc   
JT065 Ets21C_Ets_fwd3 aggctcagggggccaaatccgccgcatgccaggctca   
JT066 Ets21C_Ets_rev3 tgagcctggcatgcggcggatttggccccctgagcct   
APPENDIX – PRIMER LIST 
 
109 
JT067 Ets21C_Pnt fwd_new gccatctcctcgaaggaacagcttataccacgcc   
JT068 Ets21C_Pnt rev_new ggcgtggtataagctgttccttcgaggagatggc   
JT069 Ets21C_Ets fwd_3 new aggctcagggggccaaatcgccgcatgccaggctca   
JT070 Ets21C_Ets rev_3 new tgagcctggcatgcggcgatttggccccctgagcct   
JT071 pGEM Oligo_ rev gtaagcttgtaagcaatttctgttag   
JT072 pGEM Oligo_rev_2 tacggcagttagaaattgtaagc   
JT073 VDRC_6212 Fos fwd cgcgaattcctggagaagcggggcgagag    
JT074 VDRC_6212 Fos rev cgctctagaatgcccgtaatcgtgccgttg   
JT075 AP-1Mut_det rev tggcctagtccgtatgagtcac   
JT076 AP-1Mut_det fwd atcggcggatgagtcacct   
JT077 BacA08 inwards fwd caagtaggcatggcatggac   
JT078 BacA08out rev cgaagaaaacgggcatcagt   
JT079 AP-1Mut_seq fwd ctgtggcaggaagagcaagt   
JT080 AP-1Mut_seq rev tgcgtttattggtagcctgc   
JT081 AP-1Mut_seq rev2 tggatgatggaaccagaaaag   
JT082 AP-1Pos_det_rev cctagtccgtaccgtccattg   
JT083 AP-1Mut_last fwd agacttttgcgaccatgagc   
JT084 AP-1Mut_last rev ggcgtggtgattgtaggaac   
JT085 XmajI PCR fwd tcgcaggtaaattagcaaggc   
JT086 AP-1 new PCR 1fwd tcgcagcatcgttcacaaaa   
JT087 Pfl23II_PCR rev tctcggtgttcagcaccac   
JT088 Ets21Cp_Acc65I ggtaccatggccattctacagaatagc Acc65I 
JT089 Ets21CphosMutA_Stop_XbaI tctagatcagttgaatgcatttgtggtgggtgcgacc XbaI 
JT090 Ets21CphosMutG_Stop_XbaI tctagatcagttgaatgcatttgtggtgggtccgacc XbaI 
JT091 Ets21CphosMutA_XbaI ggtcactcccaccacaaatgcattcaactga XbaI 
JT092 Ets21CphosMutG_XbaI ggtcggacccaccacaaatgcattcaactctaga XbaI 
JT093 Ets21CphosMutA_Stop_XbaIN tctagactagttgaatgcatttgtggtgggtgcgacc XbaI 
JT094 Ets21CphosMutA_HA_BssHII gcgcgcggtcactcccaccacaaatgcattcaactga BssHII 
JT095 Ets21C_cds rev2 agacgctccggttggagt   
JT096 A08_fragment rev actgtgatagtcgccctgct   
JT097 white 2 fwd tttgtgacctgttcggagtg   
JT098 Ets21CwtXbaI2 rev ctctagactagttgaatgcatttgtgg XbaI 
JT099 Ets21C Ex3 fwd2 gcggatgagtcaccttgatt   
JT100 Bac_phosMutA_fwd ccggtcgcacccaccacaaatg   
JT101 Bac_phosMutA_rev catttgtggtgggtgcgaccgg   
JT102 Ets21CwtXbaI3 rev gtactctagactagttgaatgcatttgtgg XbaI 
JT103 BacA08_geno rev ccgttccaaatgtctggtct   
APPENDIX – PRIMER LIST 
 
110 
JT104 Fos rev out atgtactgcgtttgctgctg   
JT105 Fos fwd out catcggcaacaacatgaact   
JT106 Ets21C_gene_NotI fwd gcggccgcaccttttgccaaatatcgga NotI 
JT107 Ets21C_gene_Acc65I rev ggtaccgccaccaaactcccgaaaa Acc65I 
JT108 Ets21C_gene_NotI gcggccgctggaatgtttcaaccagcaga NotI 
JT109 Ets21C_gene_Acc65I rev agcagcacacgtcaacaatc Acc65I 
JT110 Ets21C_gene_NotI2 gcggccgctttcaaccagcagatactaa NotI 
JT111 Fos_RA_end fwd gcaccttcaacttcgactcc   
JT112 Ets21C_HAXbaI gatctctagacgtgacgtaagctagcacta XbaI 
JT113 Ets21C_NheI attctgctagcatggccattctacagaatag NheI 
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